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Abstract 
The topic of my doctoral dissertation is probing the structural features of 
caveolin-1.  Caveolin-1 is responsible for the formation of caveolae which are 50-100 
nm diameter invaginations in cell membrane.  The unique feature of caveolin-1 is the 
transmembrane domain which has a horseshoe conformation where both the N- and 
C- termini are facing the cytoplasm and the polypeptide chain turns inside the lipid 
bilayer.  In Chapter 1, expression and purification methods are discussed in order to 
obtain high yield of hydrophobic proteins.  Trp Leader fusion system was employed to 
send toxic membrane proteins into the inclusion bodies to protect the cells.  Also, 
optimization of purification methods are discussed to obtain high purity membrane 
proteins, especially caveolin-1 constructs.  In Chapter 2, the horseshoe topology of 
caveolin-1 transmembrane domain (96-136) was investigated.  Caveolin-1(96-136) 
displays a helix-break-helix motif and G108, I109, and P110 were responsible for the 
break region which is a putative turn.  Various point mutations were performed to give 
insight into these three residues.  In Chapter 3, the caveolin-1 P132L mutation was 
probed.  The P132L mutation is a naturally occurring point mutation that is found in 
16% of breast cancer patients.  Comparison of the wild-type and P132L mutation 
shows an extension of the secondary helix by 4 amino acids.  In Chapter 4, a new 
construct containing both the scaffolding domain and the transmembrane domain was 
studied to figure out whether the scaffolding domain is part of the transmembrane 
domain or a separate domain.  CSI analysis of caveolin-1(82-136) shows that the 
scaffolding domain is an extension of the first helix in the transmembrane domain 
which suggests that the scaffolding domain is not a separate domain.  In Chapter 5 
various methods of incorporation of caveolin-1 constructs into bicelles and application 
of bicelles are investigated.  Various methods were able to incorporate small amount of 
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caveolin-1 constructs into the bicelles but not at a concentration for NMR studies.  
Moreover, bicelles were used as templating medium to form periodic meso-porous 
material. 
 3 
Introduction 
Caveolae  
 The cell membrane is a semipermeable lipid bilayer found in all cells that 
contains a variety of biomolecules (Figure 1a).  Caveolae are 50 to 100 nanometer 
invaginations located in the plasma membrane of cells (1, 2, 3) (Figure 1b).  Caveolae 
are particularly abundant in endothelial cells, smooth muscle cells, macrophages, 
cardiac myocytes, and fibroblasts (2, 3, 4, 5).  Caveolae act in a variety of cellular 
process including cell-cell signaling, membrane trafficking, calcium signaling, and lipid 
recycling (6).  These long lived highly-curved structures serve as a platform for 
signaling processes and significantly increase the effective surface area of the 
membrane, allowing for greater receptor packing density.  The major constituents of 
caveolae include a array of biomolecules such as cholesterol, sphingolipids, and most 
notably, the caveolin protein (6, 7, 8).  Although, these components are distributed 
throughout the membrane, they are highly enriched in caveolae.  The roles of these 
biomolecules are proposed to promote bilayer rigidity membrane curvature, allowing 
caveolae to exist as static structures.  Although the exact role of cholesterol plays in 
caveolae has not been completely fleshed out, it is clear that these biomolecules are 
important because a loss in caveolae is detected when cholesterol is removed from 
plasma membrane (7, 8).  The most abundant and important protein in caveolae is 
caveolin, which is classified as an integral membrane protein.  Significantly, it has been 
shown that caveolae are obliterated when the caveolin gene is silenced (9).  Moreover, 
misregulation and mutations to caveolin have been implicated in a variety of disease 
states including cancer, muscular dystrophy, Alzheimer's, and heart disease (10, 11, 
 4 
12, 13, 14).  Therefore, caveolin is necessary for the caveolae formation and proper 
cell function.   
 5 
 
 
a) b)
Inside of cell
Outside of cell
Figure 1.  a) Cell membrane.  b) Tunneling electron micrograph of caveolae, Stan, R.
Biochim Biophys Acta (2005) 1746, 334-348.  Red arrows denote caveolae.   
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Caveolin 
Caveolin exists as three isoforms: caveolin-1, caveolin-2, and caveolin-3 which 
have very similar primary sequences (Figure 2).  Each protein is approximately 24 kD 
in size, and caveolin-1 appears to be the most ubiquitous and is necessary for 
caveolae formation.  Caveolin-2 is often co-expressed with caveolin-1 in most cells, 
while caveolin-3 is located primarily in skeletal and muscle cells.  Importantly, caveolins 
are thought to form high-order homo- and hetero- oligomers in vivo that create a 
scaffold that supports caveolae formation (15, 16). 
Previous investigations have postulated that the caveolin protein can be divided into 
four distinct domains: a soluble N-terminal domain, a scaffolding domain, a 
transmembrane domain, and a C-terminal domain.  The N- terminal domain is soluble, 
and is exposed to the cytoplasm and not likely interacting with the cell membrane.  
Studies have revealed that the N-terminal domain does not appear to be structured 
(17).  The scaffolding domain is predicted to form an amphipathic helix that rests on the 
surface of the membrane.  The transmembrane domain of caveolin is buried deep 
inside of the membrane and adopts a putative horseshoe topology, in that the N- and 
C- termini reside within the cytoplasm.  The C-terminal domain consists of an 
amphipathic helix that is proposed to rest on the membrane surface.  Moreover, 
caveolin-1 has three palmitoylation sites at cysteine 133, cysteine 143, and cysteine 
156 which help in anchoring the protein to the membrane (18, 19).  A highly unusual 
feature of the caveolin protein is the length of the transmembrane domain (Figure 3).  
The transmembrane domain is proposed to be 33 amino acids long and therefore is too 
long to span the bilayer once and too short to span the bilayer twice since the average 
single spanning transmembrane domain requires 20-25 amino acids.  In addition, there 
is no soluble region within the transmembrane region that would facilitate a complete 
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traverse into the extracellular space.  This unusual length of the transmembrane 
domain gives rise to two plausible orientations of this protein.  In one orientation, the 
transmembrane domain of caveolin penetrates the bilayer diagonally or as kinked helix 
to have N- and C- termini on different sides of membrane.  The second possibility 
suggests that the transmembrane domain has a turn inside the lipid bilayer and 
therefore both the N- and C- termini are located on the same side of plasma membrane.  
Studies utilizing glycosylation mapping shows that both N- and C- termini of caveolin 
are facing same side of membrane (20).  This unusual horseshoe topology is 
supported by a variety of in vivo studies which include immunofluoresence, 
immunoelectron microscopy, and antibody epitope mapping (15, 16, 20, 21, 22, 23, 24).  
The results of these studies have led to the postulation that the transmembrane 
domain forms a horseshoe structure in the membrane (Figure 4).  Furthermore, the 
intra-membrane horseshoe conformation is thought to be a plausible structural 
mechanism that allows the protein mediated induction of membrane curvature.  This 
can be visualized best by imagining caveolin as a wedge which intercalates in between 
lipids asymmetrically.  This asymmetric insertion of caveolin into the lipid bilayer 
perturbs the inner leaflet more than outer leaflet.  This unbalanced stretching curves 
the membrane to create caveolae (Figure 5).   
Since the transmembrane domain might be critical for the mechanism of caveolae 
formation, the primary structure of caveolin-1 has been investigated for structural 
motifs exhaustively.  One overarching theme is the level of conservation within the 
transmembrane domain across different species (E elegans to H. sapiens) and across 
isoforms.  Specifically, two proline residues, proline 110 and proline 132, are 
conserved in all isoforms and different organisms (Figure 6).  It seems as though these 
two proline residues are playing critical roles.  The model of caveolin is based on 
 8 
primary sequence arguments presented by Parton and co-workers suggest that proline 
at position 110 could be at pivot point of this unusual horseshoe topology (25).  
Moreover, Epand and co-workers showed in an in vivo study that the N-termini of 
caveolin are exposed to outside of the cell when proline 110 is mutated to alanine (26).  
It is overly presumptuous to identify proline 110 as the most critical amino acid for the 
horseshoe conformation because proline is found in many non-horseshoe turns and 
the study done by Epand and co-workers failed to identify the location of the C- 
terminus.  However, proline 110 still seems to be a critical amino acid for the formation 
of the horseshoe topology.  This is not surprising as some amino acids, particularly 
proline and glycine, are often found in the tight turns because of the rigidity of proline, 
which induces turns, and the high degree of freedom of glycine which is less 
constricted conformationally.  Interestingly there is another conserved proline at 
residue 132 which is also in the transmembrane domain of caveolin.  The mutation of 
this proline to leucine is a naturally occurring mutation often found in breast cancer 
patients (13, 27, 28, 29, 30, 31).  A diminished number caveolae is an observed 
phenotype when this mutation occurs.  The P132L mutation has been found to result in 
the retention of caveolin to the level of the Golgi apparatus.  Very little or no caveolin 
reach the final destination which is the plasma membrane.  It is still not clear how this 
mutation disrupts normal caveolin function but misfolded proteins are usually retained 
in the Golgi.   
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Figure 2.  Sequence alignment of three caveolin isoforms (Homo Sapiens); 
caveolin-1, caveolin-2, and caveolin-3. 
Caveolin-1 1   MSGGKYVDSE GHLYTVPIRE QGNIYKPNNK AMADELSEKQ 40
Caveolin-2 1                  MGLETE KADVQLFMDD DSYSHHSGLE 26 
Caveolin-3 1                                MMA EEHTDLEAQI 13 
Caveolin-1 41  VYDAHTKEID LVNRDPKHLN DDVVKIDFED VIAEPEGTHS 80 
Caveolin-2 27  YADPEKFADS DQDRDP-HRL NSHLKLGFED VIAEPVTTHS 66 
Caveolin-3 14  VKDIHCKEID LVNRDPKNIN EDIVKVDFED VIAEPVGTYS 53 
Caveolin-1 81  FDGIWKASFT TFTVTKYWFY RLLSALFGIP MALIWGIYFA 120
Caveolin-2 67  FDKVWICSHA LFEISKYVMY KFLTVFLAIP LAFIAGILFA 105
Caveolin-3 54  FDGVWKVSYT TFTVSKYWCY RLLSTLLGVP LALLWGFLFA 93 
Caveolin-1 121 ILSFLHIWAV VPCIKSFLIE IQCISRVYSI YVHTVCDPLF 160
Caveolin-2 106 TLSCLHIWIL MPFVKTCLMV LPSVQTIWKS VTDVIIAPLC 145
Caveolin-3 94  CISFCHIWAV VPCIKSYLIE IQCISHIYSL CIRTFCNPLF 133
Caveolin-1 161 EAVGKIFSNV RINLQKEI 178 
Caveolin-2 146 TSVGRCFSSV SLQLSQD  162 
Caveolin-3 134 AALGQVCSSI KVVLRKEV 151 
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Figure 3.  a) Hydropathy plot of caveolin-1 based on primary sequence.  b) Primary 
sequece of caveolin-1 transmembrane domain.  Hydrophobic stretch is approximately
33 amino acids (red). 
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MSGGKYVDSE GHLYTVPIRE QGNIYKPNNK AMADELSEKQ VYDAHTKEID 
LVNRDPKHLN DDVVKIDFED VIAEPEGTHS FDGIWKASFT TFTVTKYWFY 
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b)
Figure 4.  a) Topology of caveolin-1.  b) Sequence of caveolin-1. Blue denotes
scaffolding domain, red denotes transmembrane domain, and green denotes
palmitoylation. 
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Figure 5.  a) Proposed mechanism of caveolae fomation induced by caveolin.   
b) Topology of caveolin in caveolae. 
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Figure 6.  Sequence alignment of caveolin-1 in different organisms. 
Caveolin-1 Human   1  MSGGKYVDSE GHLYTVPIRE QGNIYKPNNK 30 
Caveolin-1 Dog     1   MSGGKYVDSE GHLYTVPIRE QGNIYKPNNK 30 
Caveolin-1 Mouse   1   MSGGKYVDSE GHLYTVPIRE QGNIYKPNNK 30 
Caveolin-1 Chicken 1   MSGTKYVDSE GFLYAAPVRE QGNIYKPNNK 30 
Caveolin-1 Xenopus 1   MQDR--VMAE ---------E Q-SFYEG--- 15 
Caveolin-1 Human   31  AMADELSEKQ VYDAHTKEID LVNRDPKHLN 60 
Caveolin-1 Dog     31  AMAEEMSEKQ VYDAHTKEID LVNRDPKHLN 60 
Caveolin-1 Mouse   31  AMADEVTEKQ VYDAHTKEID LVNRDPKHLN 60 
Caveolin-1 Chicken 31  MMADELSEKA VHDVDTKEID LVNRDPKHLN 60 
Caveolin-1 Xenopus 16  --------KI AKDLLTKEID LVDRDPKRIN 45 
Caveolin-1 Human   61  DDVVKIDFED VIAEPEGTHS FDGIWKASFT 90 
Caveolin-1 Dog     61  DDVVKIDFED VIAEPEGTHS FDGIWKASFT 90 
Caveolin-1 Mouse   61  DDVVKIDFED VIAEPEGTHS FDGIWKASFT 90 
Caveolin-1 Chicken 61  DDVVKIDFED VIAEPEGTHS FDGIWKASFT 90 
Caveolin-1 Xenopus 46  DSVIKVDFED VIAEPQGTHS FDGVWKASYT 75 
Caveolin-1 Human   91  TFTVTKYWFY RLLSALFGIP MALIWGIYFA 120 
Caveolin-1 Dog     91  TFTVTKYWFY RLLSALFGIP MALIWGIYFA 120 
Caveolin-1 Mouse   91  TFTVTKYWFY RLLSTIFGIP MALIWGIYFA 120 
Caveolin-1 Chicken 91  TFTVTKYWFY RLLSAIFGIP MALIWGIYFA 120 
Caveolin-1 Xenopus 76  TFTVTKFWCY RILSAAIGIP LSIVWGFIFA 105 
Caveolin-1 Human   121 ILSFLHIWAV VPCIKSFLIE IQCISRVYSI 150 
Caveolin-1 Dog     121 ILSFLHIWAV VPCIKSFLIE IQCISRVYSI 150 
Caveolin-1 Mouse   121 ILSFLHIWAV VPCIKSFLIE IQCISRVYSI 150 
Caveolin-1 Chicken 121 ILSFLHIWAV VPCIRSYLIE IQCISRVYSI 150 
Caveolin-1 Xenopus 106 LISFCHIWAV VPCIKSYQIE THCLGRIFSL 135 
Caveolin-1 Human   151 YVHTVCDPLF EAVGKIFSNV RINLQKEI 178 
Caveolin-1 Dog     151 YVHTFCDPFF EAVGKIFSNI RINMQKET 178 
Caveolin-1 Mouse   151 YVHTFCDPLF EAIGKIFSNI RISTQKEI 178 
Caveolin-1 Chicken 151 CIHTFCDPLF EAMGKVFSSI RATVRKEI 178 
Caveolin-1 Xenopus 136 CTHTFCDPLF EALGKIFSSI KVTLQKNM 155 
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Membranes 
As is the case for determining structural and functional aspects of any 
membrane protein in its most native like state, an accurate mimic of the cells plasma 
membrane is required to study the caveolin-1 protein.  Membrane proteins including 
caveolin-1 are mostly composed of hydrophobic amino acids which cause them to be 
extremely insoluble in aqueous buffers.  The insolubility of membrane proteins makes 
them more challenging to work with.  Often times it is necessary to add strong 
detergents to aqueous buffers in order to solubilize membrane proteins.  Unfortunately, 
the addition of detergents can influence the overall structure of the membrane protein 
introducing an unwanted bias.  Therefore, it is critical to choose a detergent system 
that most closely mimics the cell membrane environment.   
Lipids aggregates that are typically used to study membrane proteins are micelles and 
vesicles.  Micelles have dynamic properties, but it is not the ideal mimic of the cell 
membrane because of its extreme curvature and lack of a planar bilayer region (Figure 
7a).  These deficiencies can lead to a biased conformation of membrane proteins that 
does not accurately depict the structure of these proteins in their native form.  However, 
micelles are still mostly used in solution NMR studies because there is no other reliable 
mimic that can be adapted easily and the secondary structure of protein is usually 
conserved (32).  Vesicles are perhaps the best mimic because they have less 
curvature than micelles as well as a distinct bilayer region, and also possess hollow 
centers much like an actual cell (Figure 7b).  The biggest drawback to using vesicles, 
however, is that they lack the dynamic properties of micelles, and their relatively large 
size makes them difficult to adapt for NMR studies.  Bicelles, on the other hand, 
combine the dynamic property of micelles with the bilayer properties of vesicles (33, 34, 
35, 36, 37, 38, 39).  A bicelle is a discoidal lipid aggregate composed of long-chain 
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phospholipids and detergent molecules (Figure 7c).  The center, planar region of the 
bilayer is typically composed of a long-chain phospholipid, while the curved rim of the 
bicelle is composed of the short chain phospholipids or detergents that encapsulate 
and isolate the center bilayer from the aqueous surroundings.  For example, a 
commonly used long-chain phospholipid is dimyristoyl-phosphatidylcholine (DMPC) 
and a short-chain is dihexanoyl-phosphatidylcholine (DHPC).  The characteristics of 
the bicelle can be varied to suit many different applications by changing the length of 
the phospholipid chain or the head groups of the phospholipids thereby altering the 
charge characteristics of the bicelle.  For example, the size of a bicelle is dependent on 
q, which is the molar ratio of the long-chain lipid (DMPC) to the shorter chain lipid 
(DHPC).  For most solution-phase studies, a q of 0.5 is used, however, larger bicelles 
can be used depending on the application simply by increasing the q.  Also at this q 
value, the bicelles have a diameter of 82 Å, which is an appreciable bilayer region 
sufficient to accommodate full-length proteins.  Bicelles have unique properties based 
on the q value and identity of components making up the rim and planar regions.  
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Figure 7.  Mimic of cell membrane.  a) Micelle.  b) Vesicle.  c) Bicelle. 
b)a)
c)
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Biophysical techniques 
There are several methods to study the structure of proteins.  One commonly 
used method to study secondary structure is circular dichroism spectroscopy (40, 41, 
42).  Circular dichroism spectroscopy is measures the differential absorption of left and 
right handed circularly polarized light.  When circular polarized light passes through a 
sample that has chiral centers, the molecules will change polarization of the light.  
Based on changes of the circularly polarized light global secondary structural 
characteristics can be revealed.  Advantageously, the common secondary structural 
motifs within proteins give rise to predictable patterns in circular dichroism spectra.  For 
example, a protein that contains α-helical properties will give rise to a spectrum that 
has two minima at 208 nm and 222 nm.  The β-sheet property shows minima at 217 
nm and random coil shows a minimum at 204 nm.  Based on this information, global 
secondary structure of protein can be revealed using computer program which will give 
the relative contribution of each structural motif to the entire spectrum (45, 46, 47). 
To study the tertiary structure of proteins, two methods are primary used; 
nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography.  Each 
method has advantages and disadvantages.  In X-ray crystallography, samples have to 
be crystallized in order to carry out the analysis.  This is especially difficult for 
membrane proteins as they often do not form usable crystals.  Also, crystallized 
proteins can be forced to adopt a conformation that may not be representative of their 
native form in solution.  For NMR, full-length proteins (>30kD) are difficult due to their 
long reorientation rates that results in acceptable spectral broadening.  Therefore, 
separate experiments can be run to obtain information about small segments of a 
protein.  Although, this is not ideal, NMR is advantageous compared to X-ray 
crystallography because the protein can be analyzed in solution, which more closely 
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mimics the natural dynamic environment of the protein. Moreover, it is also possible to 
investigate the influence of other solution properties that will undoubtedly be important 
to nuances in protein structure such as pH and temperature.  For NMR analysis, using 
traditional one-dimensional NMR to solve protein structure is virtually impossible due to 
the presence of an overwhelmingly large number of resonances in a given protein 
sample.  There would be a high degree of signal overlap which would preclude an 
accurate spectrum assignment.  To circumvent this problem, two and three 
dimensional spectroscopic methods are utilized.  Initially, a Heteronuclear Single 
Quantum Coherence (HSQC) spectrum will be obtained by incorporating uniformly 
isotopic labeled nitrogen into a protein and measuring the resonances of both 15N and 
1H.  The HSQC spectrum will provide critical information about the backbone of the 
protein because each peptide bond formed between amino acids contains an amide 
proton attached to a nitrogen atom which will give rise to a signal.  Consequently, the 
number of peaks in the spectrum should correspond with the number of peptide bonds 
in the protein (40).  The wide dispersion of the HSQC spectrum suggests that each 
amino acid is surrounded by unique environment.  Therefore, a spectrum that has well 
dispersed peaks represents a well-structured protein.  Therefore, based on quality of 
HSQC experiment, we can decide to move on to three dimensional experiments for 
backbone assignment.  
Many in vivo studies have been carried out on caveolin, but there are few 
biophysical studies that are definitive in presenting a structural model for caveolin.  
This is mainly because of difficulty in handling this protein as it is extremely 
hydrophobic.  Furthermore, there are no biophysical studies to our knowledge that 
have investigated the unusual structure of the transmembrane domain of caveolin.  
Therefore, we investigated the structure of caveolin-1 transmembrane domain.  In 
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particular, we focused on two proline residues which reside in the transmembrane 
domain of caveolin-1.  Caveolin-1 was chosen because it is the most ubiquitous and 
the transmembrane domains of three isoforms are highly conserved.  To investigate 
the structure of the caveolin-1 transmembrane domain we utilized experiments as 
outline below.  First we over-expressed caveolin-1 transmembrane domain.  The Trp 
leader fusion system was used to bring caveolin into inclusion bodies to obtain high 
yield.  Inclusion bodies are subjected to inclusion body purification methods to obtain 
extremely pure caveolin-1 protein.  Cyanogen bromide cleavage is used to separate 
the target protein from the fusion partner and the protein is then isolated using C4 
reverse phase HPLC and verified by MALDI-TOF mass spectroscopy (28, 43, 44).  
Second, the pure protein is incorporated into a membrane mimic and is then subjected 
to CD and NMR spectroscopy analysis to obtain structural information.  Analyses of CD 
data were performed using a web-based computer program called Dichroweb and 
NMR data was analyzed using various computer programs such as NMRPipe and 
TALOS+ (45, 46, 47, 48, 49).  After obtaining and analyzing wild-type caveolin-1 
transmembrane domain, point mutations of proline residues were performed to 
investigate the role of these prolines.  Moreover, a model of caveolin-1 was proposed 
based on direct structural experiments for the first time. 
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Chapter 1. Expression and Purification of Membrane Proteins 
Abstract 
With the growing interest in membrane protein structure and function, a reliable 
high-yielding method for the expression and purification of highly insoluble membrane 
proteins is desirable.  For these studies, E.coli was used as the host for membrane 
protein expression.  Over expression of membrane proteins is typically toxic to E.coli, 
therefore, the expression system that is described in this chapter uses a Trp leader 
protein fusion system where the membrane protein of interest is fused to the Trp leader 
protein sequence.  During protein expression, the Trp Leader membrane protein fusion 
directed way into inclusion bodies in order to avoid premature cell death from toxicity of 
the membrane protein.  The inclusion bodies are carried through a series of wash 
steps in order to obtain semi-pure proteins.  For the purification of a small 2 kD 
membrane protein PFOA nickel-affinity chromatography was used to obtain highly pure 
fusion protein.  Cyanogen bromide cleavage was performed to separate the target 
protein from the Trp Leader fusion partner, and C4 reverse phase high performance 
liquid chromatography was carried out to isolate the target membrane protein.  The 
product was verified by matrix-assisted laser desorption and ionization-time of flight 
(MALDI-TOF) mass spectroscopy.  This expression method was also adapted as a 
cost effective means to obtain isotopically labeled proteins.   
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Introduction 
It is well known that approximately one third of the human genome encodes for 
membrane proteins.  Membrane proteins play a critical role in cell signaling, signal 
transduction, and growth regulation (21).  There are three classes of membrane 
proteins. First, integral membrane proteins (transmembrane protein) span membrane 
and are composed mostly of hydrophobic amino acids.  Second, peripheral membrane 
proteins associated with lipid bilayer and only penetrate the surface of the lipid bilayer.  
Lastly, lipid anchor proteins attached to lipid bilayer anchoring to lipid head group.  
Integral membrane proteins have been shown to play an important role in the function 
of membrane proteins.  For example, the pore structure of a transmembrane domain of 
an ion channel allows specific ions to pass through membranes (50, 51, 52).  Therefore, 
reliable and efficient methods for the expression and purification of transmembrane 
domains are needed in order to drive progress in this area forward.  In vitro research 
on integral membrane proteins is still in its infancy compared to soluble proteins due to 
the fact that membrane proteins are very hydrophobic and highly insoluble in traditional 
buffers which presents significant challenges when it comes to producing them.  
Membrane proteins can be synthesized using traditional molecular cloning methods 
whereby an organism is used as a vector for protein expression.  Typically, E.coli is the 
organism of choice for over-expressing proteins because it is easy to culture and 
obtain protein yields are high (53, 54).  However, in the case of membrane proteins, 
expression is difficult due to the fact that mammalian membrane proteins are highly 
toxic to the E.coli organism.  The over-expression of these proteins leads to premature 
cell death before a sufficient protein yield can be achieved.  To circumvent this problem, 
membrane proteins can be expressed directly into inclusion bodies.  To achieve this  a 
fusion system is utilized where one protein, usually a protein that E.coli expresses 
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natively , is attached to the target protein through the preparation of a gene that 
encodes the fusion protein.  The fusion partner directs the entire fusion protein into 
inclusion bodies, which are comprised of misfolded, insoluble aggregated proteins.  
The inclusion bodies protect the host organism from premature cell death and 
premature degradation.  This has allowed high expression levels of membrane proteins 
to be obtained using E.coli.  Usually a series of buffered wash steps is employed to 
semi purify the inclusion bodies after they have been liberated from the E.coli cells (43).   
Small proteins (approximately 2kD) are more difficult to express compared to larger 
membrane proteins (approximately 4-6kD) using the current established methods.  The 
most common method of obtaining small proteins is solid-phase synthesis; however, 
there are limitations to this method as well.  For example, nuclear magnetic resonance 
(NMR) studies require isotopic-labeled nitrogen and carbon in milligram quantities, but 
for solid-phase synthesis, this is not cost effective because reagents are very 
expensive and the yield is very low.  Few approaches to expressing and purifying 
membrane proteins have been successful, yet there are no reliable or reproducible 
methods for preparing high quantities of small hydrophobic proteins.  In this study, a 
reliable method for producing milligram quantities of small hydrophobic protein has 
been developed.  This method can easily be adapted for the preparation of isotopically-
labeled proteins for NMR characterization. 
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Material and Methods 
Construct Design 
Caveolin-1(96-136) 
 Caveolin-1(96-136) contains the full intact transmembrane domain of the 
caveolin-1 protein based on the hydrophobicity analysis of the protein’s primary 
sequence.  Since caveolin is known to create curvature in the membranes of cells, the 
working hypothesis is that the transmembrane domain of the protein is playing a key 
role.  NMR is not conducive to large membrane protein structure, so the full-length 
caveolin protein structure was not initially investigated.  The transmembrane region is 
predicted to form a horseshoe loop structure, which effectively curves the bilayer to 
form caveolae.  The construct of the caveolin-1 protein was designed as a fusion to the 
Trp leader protein (Figure 1-1).  The Trp leader and caveolin-1 transmembrane domain 
(96-136) fusion protein was used because the Trp leader protein promotes higher 
expression levels of caveolin-1(96-136).  Trp leader promotes protein expression into 
inclusion bodies and brings the fused caveolin-1(96-136) into the inclusion bodies with 
it.  Since caveolin-1(96-136) is extremely hydrophobic, expression under soluble 
conditions will quickly create a toxic environment that will kill the bacterial cells in which 
the protein is being expressed.  This results in a lower protein yield.  Therefore, the 
inclusion body expression method is ideal as it allows expression of caveolin-1(96-136) 
at much higher levels because the inclusion bodies protect the expression host from 
the cytotoxic caveolin protein. Additionally, a methionine residue is added between Trp 
leader and caveolin-1(96-136) which allows the caveolin-1(96-136) protein to be 
cleaved from the fusion protein using cyanogen bromide.  Because cyanogen bromide 
cleavage occurs after all methionine residues, and caveolin-1(96-136) contains one 
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native methionine residue, this native methionine was mutated to leucine (M111L) 
based on sequence homology to caveolin-2 and caveolin-3 isoforms.  Also one 
cysteine residue was mutated to serine (C133S) to avoid unwanted disulfide bonding.  
The mutation of cysteine to serine is considered conservative as this mutation was 
shown to not interrupt correct caveolin-1 traffinkng to the plasma membrane.   
Caveolin-1(122-142) 
The Caveolin-1(122-142) protein represents a region of the protein that has 
been implicated in a variety of disease states such as cancer.  In particular, a P132L 
mutation in caveolin is associated with poorly functioning caveolin protein and serves 
as a marker for various disease states including breast cancer.  In order to study the 
effects of this significant mutation, we have prepared a construct of the caveolin protein 
that encompasses residues 122-142.  In this construct, the P132 residue resides at the 
center of the Caveolin-1(122-142) protein, and is flanked by 10 residues on each side.  
This construct was prepared in the same manner as the previous constructs using the 
Trp leader fusion system.  However, because this protein is so small, a double fusion 
system was also employed.  The ubiquitin protein was attached in tandem to the Trp 
leader protein followed by caveolin-1(122-142).  To facilitate the purification of this 
construct, an octa-histidine tag was added to the front of the construct so that Ni-NTA 
affinity chromatography could be used for purification.   
RfbP  
The RfbP protein is approximately 25 kD in size and is native to the bacterium, 
Salmonella enteric.  RfbP transfers a galactose moiety from uridine 5’-
diphosphogalactose to undecaprenylphosphate to form undecaprenyl-pyrophosphate-
galactose (55, 56).  Undecaprenol is extremely hydrophobic and it is suspected that the 
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transmembrane domain of the RfbP protein may be required for proper function and 
activity.  To decipher the mechanism of galactose transfer it is important to solve the 
structure of the transmembrane domain of this protein.  To design the construct for 
these studies, the single spanning transmembrane domain of RfbP was used.  This 
domain is approximately 20 amino acids in length and contains extremely hydrophobic 
residues.  To enhance the solubility of this construct extra residues were added to both 
ends of the transmembrane domain.  The final construct contained RfbP residues 18-
51 which has an approximate molecular weight of 4.9 kD.  The Trp leader fusion 
system was used to express this protein.  
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CNBr Cleavage
Trp leader M Target protein (4-6kD)
Target protein (4-6kD)
Trp leader_Ubiquitin M Caveolin-1(122-142)
Caveolin-1(122-142)
CNBr Cleavage
Figure 1-1.  Design of fusion protein construct using Trp leader and Trp leader-
Ubiquitin.  Separation from the fusion protein by cyanogen bromide was
accomplished by inserting a methionine between the fusion protein and the protein of
interest.  Target proteins investigated were various caveolin-1 constructs and RfbP.   
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Cloning and Expression 
First, caveolin-1(96-136), caveolin-1(122-142) and RfbP(18-51) genes were 
prepared by obtaining two nucleotide oligomers with a 25 base pairs complementary 
overlap (Figure 1-2).  The caveolin-1(96-136) and RfbP (18-51) genes were each 
cloned into the pET-24a vector containing the Trp leader fusion using the BamH1 and 
EcoR1 restriction sites. The Caveolin-1(122-142) gene was cloned into a pET-24a 
vector containing the N-terminal octa-histidine Trp leader-ubiquitin sequence using 
BamH1 and EcoR1 as well (Figure 1-3).    
The forward and reverse primers (Appendix 1-1) were prepared at a 2.0 µg / µL 
concentration in sterile distilled water.  A PCR reaction was prepared using 1 µL of 
each primer, 5.0 µL of 10X Thermapol buffer, 0.4µL of dNTPs (100 mM total), and 1µL 
of Taq polymerase on a 50-µL scale with volume adjustment using sterile water.  The 
thermal cycler was set to the following cycling conditions:  1 cycle at 95 °C for two 
minutes, 5 cycles at 95°C for 15 seconds, 45 °C for 15 seconds, 72 °C for 1 minute, 1 
cycle at 72 °C for 5 minutes, 4 °C for an indefinite period (Appendix 1-2).  The PCR 
product was purified using the “PCR Quick cleanup procedure” outlined in the Qiagen 
Gel Extraction kit.  The purified PCR product was digested with the restriction enzymes 
BamH1 and EcoR1 to create “sticky ends”, which allows the gene to be incorporated 
into the desired vector.  The desired vector was digested with BamH1 and EcoR1 in a 
separate reaction.  The digest reactions were  carried out overnight at room 
temperature on a 50 µL scale consisting of 42.5 µL of PCR product or pET-24a  vector, 
5 µL of 10X EcoR1 buffer, 1 µL of BamH1, 1 µL of EcoR1, and 0.5 µL of 100X BSA.  
The pET-24a vectors containing Trp leader or Trp leader-Ubiq fusion were obtained 
from the Komives group at UCSD.  The DNA encoding the desired protein and the 
vector were quantitated by 1% agarose gel electrophoresis.  Insertion and ligation of 
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DNA into the vector were carried out at room temperature overnight.  The reaction 
mixture containing a 1:5 ratio of vector to DNA with appropriate amount of 10X T4 DNA 
ligase buffer (based on concentration of vector and DNA) and 1 µL of T4 DNA ligase.  
After ligation, 1 µL of ligation reaction mixture was transformed into 50 µL XL1 blue 
subcloning grade cells (Appendix 1-3).  The cells were grown overnight at 37 ºC on an 
LB agar plate containing kanamycin, which allows for the selective growth of bacteria 
containing the ligated vector.  The pET-24a vector confers kanamycin resistance which 
allows for selective screening.  Colonies were picked and grown at 37 °C overnight in 5 
mL of LB broth containing kanamycin.  The cells were harvested and the DNA was 
isolated using the Qiagen Miniprep kit (Valencia,CA) procedure.  The purified DNA was 
sent to Genewiz (South Plainfield, NJ) to confirm that the correct sequence had been 
cloned in.  The sequencing results confirmed successfully transformed cells.  The 
sequenced DNA (20 ng) was transformed into E.coli BL21 (DE3) cells (100 µL) and 
was then plated kanamycin MDAG plate overnight at 37 ºC (Appendix 1-4).  BL21 
(DE3) cells are equipped with the necessary cellular machinery which will allow them to 
express the protein of interest.  To test the transformed colonies ability to express the 
target protein, a small scale growth was performed with 1 mM IPTG induction.  The 
expression level of target protein can be checked by running SDS-PAGE 
electrophoresis (Figure 1-4).  Once the colony is chosen, a large scale growth is 
performed.   
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Figure 1-2.  Synthetic preparation of target genes with 25 base pairs overlap. 
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BamH1
EcoR1
pET Plasmid
Figure 1-3.  Map of the pET-24a vector expression system containing Trp leader or
Trp leader-Ubiquitin.  Synthesized gene (red) was inserted using BamH1 and EcoR1
restriction sites. 
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Figure 1-4.  a) Test expression of caveolin-1(96-136).  Lane 1. Molecular marker, 
lane2 and 3 Uninduced / Induced Trp leader fusion protein, lane 4 and 5. 
uninduce/induced Ubiquitin fusion protein.  b) Test expression of caveolin-1(122-
142).  Lane 1. Molecular marker, lane2 and 3. Uninduced / Induced Trp leader-
Ubiquitin fusion protein.  c) Test expression of caveolin-1(122-142).  Lane 1. 
Molecular marker, lane2 and 3 Uninduced / Induced Ubiquitin fusion protein, lane 4. 
Molecular marker, lane 5 and 6 Uninduce / Induced KSI fusion protein. 
a) 1 2 3
23kD
17kD
4 5 1 2 3 4 5 61 2 3b) c)
23kD
17kD 23kD
17kD
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Cell growth and Isotope labeling 
A large-scale cell growth is performed using the auto-induction method 
developed by Studier et al (57).  For NMR studies the 15N-labeled protein constructs 
have been successfully prepared using minimal auto-inducing media containing 
15NH4Cl as the sole nitrogen source for the bacterial cells.  Moreover, other labeling 
methods are optimized to obtain protein for NMR structural studies.  The cells are 
grown to saturation in the auto-induction media and harvested (Figure 1-5).  The cells 
were harvested by centrifugation at 5,000 x g for 30 minutes at 4 ˚C.  The pelleted cells 
were washed and resuspended in ice cold saline solution (0.9% NaCl).  In this section, 
various cell growth conditions were explored in order to optimize the yield of each of 
the protein constructs.   
Rich media cell growth 
A large-scale (6-liter flask, 1-liter of media) cell growth is performed using the 
auto-induction method developed by Studier et al (57).  1-liter ZYM-5052 media is 
prepared in 6-liter Erlenmeyer flask and incubated at 37ºC for at least an hour to reach 
thermal equilibrium (Appendix 1-5).  One milliliter of starter (5mL growth in non-
inducing MDAG media (Appendix 1-6) was added for every liter of media at a shaking 
speed of 225 rpm at 37 ºC to reach saturation point.  The bacterial growth of the culture 
was monitored every hour at 600 nm until the optical density of the growth no longer 
changed.  The cells are grown to saturation in the auto-induction media and are 
harvested as previously described. 
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Uniformly labeled 15N cell growth in minimal media 
 A large scale growth for 15N labeled target protein was performed using the 
auto-induction method.  N5052 minimal media was chosen because ammonium 
chloride is the sole nitrogen source in the media (Appendix 1-5).  Substitution of 14N 
ammonium chloride to 15N ammonium chloride can effectively label protein with 15N 
nitrogen.  Like the rich media cell growth method, 1 liter of sterile minimal media is 
prepared and incubated at 37 ºC for one  hour to reach temperature equilibrium then 1 
mL of MDAG starter is added to 1 L of media.  The growth is incubated at 37ºC while a 
shaking speeds of 225 rpm for approximately 18 hours in order to reach the saturation 
point.   
13C, 15N labeling with exchanging media method 
 To assign the protein backbone using solution NMR, nitrogen and carbon 
atoms must be labeled with 15N and 13C.  In order to incorporate these isotopes into our 
protein, a cell growth was performed in M9 minimal media using a procedure that was 
optimized by Marley et al (58).  This protocol uses 13C glucose and 15NH4Cl as the only 
carbon and nitrogen sources, which forces the bacteria to incorporate these labels into 
the protein as it is synthesized.  The cell growth was started by adding 1 mL of starter 
to 1-liter of LB broth.  As soon as the optical density (600 nm) reaches 0.6 - 0.8, 
harvest the cells by centrifuging at 5000 x g for 30 minutes at 25 ºC.  Next, the cells 
were washed with 250 mL of wash buffer which is M9 minimal media without any 
nitrogen (15NH4Cl) or carbon (13C glucose) source.  After resuspension in the wash 
buffer, the cells were centrifuged at 5000 x g for 30 minutes at 25ºC.  After the cells 
have been pelleted a second time, they were resuspended in 250 mL of M9 minimal 
media containing 13C glucose and 15N nitrogen and was transferred to a sterile 6 Liter 
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flask.  The culture was incubated at 37 °C for one hour, with shaking at 225 rpm.  
Protein expression was induced by the addition of 0.8 mM IPTG.  The culture was 
incubated for another 6-8 hours and harvested.  Incorporation of 2H labeling of the 
protein for beta carbon information in the protein, the water is exchanged to deuterium 
in the M9 minimal media and is incubated twice as long in buffers before and after 
IPTG induction (approximately 2 hours before IPTG induction and 12hours after IPTG 
induction).   
Specific labeling method 
 To facilitate protein backbone assignments, specific amino acid labeling is 
necessary.  Isotopically labeled valine, alanine, phenylalanine, isoleucine, and leucine 
are introduced to the media during growth.  Slight modifications were made to the 
procedure previously described and the optimization of these growths was based on 
the method of Truhlar et al (59).  For example, to obtain only 15N-alanine-labeled 
protein, M9 minimal media supplemented with 15N alanine and a 5-fold excess of other 
14N amino acids is prepared.  First, 1 Liter of M9 minimal media is prepared in a 6 L 
beaker.  To the M9 media 500 mg of 14N amino acids and 100 mg of 15N amino acid 
were added.  After all the amino acids have been added to  the media, it was sterile 
filtered using a 0.2 µm filter and incubated at 37 ºC for one hour.  1 mL of MDAG 
starter was added to 1 Liter of media and the optical density of the growth was 
monitored at 600 nm to a final OD of 0.6.  IPTG was added to a final concentration of 1 
mM to induce protein expression and the culture was left to grow for 6 hours at 37 °C 
with shaking at 225 rpm.   
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Figure 1-5.  Cell growth profile of Trp leader caveolin-1 fusion protein. 
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Purification 
Trp Leader fusion proteins 
To isolate the protein from E.coli cells, a series of selective wash steps were 
performed (Figure 1-6) (43).  In the first wash step, the cell pellet from a 1-liter growth 
was resuspended in 200 mL of a buffer containing 20% (w/v) sucrose, 20 mM Tris-HCl 
pH 8.0 with 1 mM βME and 1 mM EDTA.  Beta-mercaptoethanol was added to a final 
concentration of 1 mM during the wash steps in order to prevent any undesired 
disulfide bond formation and to keep the methionine residue reduced, which is 
essential to the cyanogen bromide reaction.  The resuspended material was sonicated 
using a Branson tip sonifier at a power output level of 10 and a 50% duty cycle with 
vigorous stirring for 15 minutes.  The inclusion bodies and the soluble proteins are 
liberated from the bacterial cells.  The insoluble inclusion bodies and cell debris are 
separated from the aqueous proteins by centrifugation at 27,500 x g for 2 hours at 
10°C.  The pellet containing the insoluble material is subjected to a second wash step 
using 200 mL of 20 mM Tris-HCl, pH 8.0 buffer containing 1% Triton X-100 (v/v) and 1 
mM BME.  The mixture is sonicated again to resuspend the insoluble material using 
the conditions above.  The mixture is subjected to centrifugation at 27,500 x g for 1 
hour at 10°C.  The second wash step is designed to separate the broken cell 
membrane pieces along with the membrane proteins from the highly insoluble inclusion 
bodies.  The desired protein is protected from this second wash step by the highly 
insoluble inclusion bodies, which do not readily dissolve in Triton X-100.  Therefore, 
they are not removed with the supernatant in the second wash step and only 
membrane proteins that are soluble in Triton X-100 are removed.  The last wash step 
uses 100 mL of 20 mM Tris-HCl pH 8.0 containing 60% (v/v) isopropanol (Mallinckrodt, 
Hazelwood, MO) which removes any traces of the Triton X-100 detergent.  
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Resuspended pellets are centrifuged at 50,000 x g for 1 hour at 10°C.  Isopropanol is 
effective at increasing the critical micelle concentration of the Trition X-100 detergent, 
which makes it very effective at removing all traces of Triton X-100.  After the 
isopropanol wash the semi-pure inclusion bodies are dried well and solubilized in 88% 
formic acid with a dounce homogenizer and centrifuged at 50,000 x g for 30 minutes at 
25°C.  The highly insoluble inclusion bodies are soluble in 88% formic acid (JT Baker, 
Phillipsburg, NJ), which is advantageous because the cyanogen bromide cleavage 
requires highly acidic conditions for optimal cleavage.  Cyanogen bromide is added to 
the supernatant to cleave the fusion protein at the methionine position thereby 
liberating the caveolin protein from the Trp Leader fusion protein.  The cyanogen 
bromide reaction is left to proceed at room temperature for approximately 18 hours, 
and it is subsequently dried down using a vacuum concentrator (Thermo Scientific) to 
remove unreacted cyanogen bromide and formic acid.  The dry pelleted target protein 
was resuspended in a small volume of 88% formic acid; approximately 5 mL per 25 mg 
of dry protein.  The dry protein was subjected to reverse-phase HPLC to separate the 
Trp Leader protein from target protein using a C4 bonded stationary phase.  To 
separate the target protein from Trp Leader, a mobile phase with a 1% gradient was 
used beginning with 100% of solution containing 80% water / 20% acetic acid and 
changing to a solution of 80% 1-butanol / 20% acetic acid.  All peaks were collected 
and the presence of the target protein was verified using MALDI-TOF mass 
spectrometry.  The target protein was lyophilized from HFIP and stored at -20 ºC for 
later usage.   
Trp Leader_Ubiquitin Fusion Proteins 
A 2-liter cell pellet is processed the same as the Trp leader fusion protein 
mentioned above to remove the unwanted soluble and membrane-bound proteins.  
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Beta-mercaptoethanol can be added to a final concentration of 1 mM during the wash 
steps.  The semi-pure pellet was dissolved in 8% (w/v) PFOA (pentadecafluorooctanoic 
acid) (Oakwood Products, Inc. West Columbia, SC), 25 mM phosphate pH 8 buffer.  To 
facilitate the dissolution of the pellet, it was sonicated for 15 minutes to obtain a 
homogeneous solution.  The solution was centrifuged at 50,000 x g for 30 minutes at 
20 °C.  The supernatant was retained and filtered through a 0.2 micron filter before 
loading onto a nickel affinity column.  The bound material was washed with 3 column 
volumes of 1% (w/v) PFOA, 25 mM phosphate pH 8 buffer.  The bound material is 
eluted from the column using 1% (w/v) PFOA, 25 mM phosphate pH 4 solution (Note: a 
1% PFOA, 25 mM phosphate pH 8 buffer containing 250 mM imidazole can also be 
used to elute the nickel column).  Pure full-length fusion protein was successfully 
recovered and dialyzed immediately against 15-liters of 10 mM ammonium sulfate pH 8 
containing 1 mM βME (betamercaptanol) to remove PFOA.  Several buffer exchanges 
were performed to completely remove PFOA.  It is evident that most of the PFOA was 
removed because the fusion protein precipitates out of solution in the dialysis bag.  
After dialysis, the precipitated protein was collected by centrifugation at 15,000 x g for 
30 minutes at 20°C.  The pellet was dissolved in 70% formic acid and a 100-fold 
excess of cyanogen bromide was added to the cleavage reaction.  The reaction was 
bubbled under a blanket of nitrogen for 5 minutes and left to proceed rotating in the 
dark for 16 hours at room temperature.  This was sufficient for complete cleavage of 
the target protein.  The reaction mixture was dried down in a SpeedVac® concentrator 
to remove excess formic acid and cyanogen bromide.  The cleaved protein was 
dissolved in 88% formic acid (approximately 25 mg in 5 milliliters) and injected onto a 
C4 reverse-phase HPLC column.  The column was run at a flow rate of 10 mL per 
minute at a 0.6 % mL per minute gradient using a 20% acetic acid and 80% water to 
20% acetic acid and 80% butanol solution.  The desired protein was collected and 
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verified by MALDI-TOF mass spectroscopy.  The protein was dried out of the HPLC 
solvent and resuspended in a 20% HFIP solution, immediately frozen in liquid nitrogen 
and lyophilized to obtain a powder.  The lyophilized powder is stable stored at -20 ºC 
for several months. 
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Figure 1-6.  Flow chart of Trp leader and Trp leader-Ubiquitin fusion protein
purification steps.  
20% (w/v) Sucrose, 20 mM Tris pH 8
1% (v/v) Triton X-100, 20 mM Tris pH 8
60% (v/v) IPA, 20 mM Tris pH 8
88% Formic acid
CNBr Cleavage
Ni-NTA with 1% PFOA buffer
Trp leader Trp leader-Ubiquitin
Dialysis
CNBr
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Results and Discussion 
Expression  
One of the biggest challenges in working with integral membrane proteins is 
that it is difficult to obtain purified material for in vitro studies.  Extremely hydrophobic 
transmembrane proteins especially mammalian proteins ranging in size from 25 to 45 
amino acids are poorly expressed in E.coli, in general, therefore it is hard to achieve 
sufficient amounts for structural studies.  To circumvent this problem, the 
transmembrane domains of membrane proteins are typically expressed as fusion 
proteins.  For our studies Trp leader was used because it is native to E.coli, is readily 
expressed and brings attached proteins into inclusion bodies.  This fusion system 
dramatically improves expression level of the transmembrane proteins.  To find a 
suitable fusion partner, several proteins were chosen and tested for their expression 
level of transmembrane domains of membrane proteins.  Expression with the Trp 
leader fusion system directs toxic membrane proteins into inclusion bodies so that high 
expression levels can be achieved.  This is likely due to the fact that mammalian 
membrane proteins are toxic to the cell during overexpression.  The E.coli membrane 
has limited space to accommodate membrane protein insertion. Therefore, unless 
protein is precipitated into inclusion bodies the membrane protein will easily saturate 
the E.coli membrane and lead to premature cell death.  Another well-known fusion 
partner, ubiquitin was also tested.  The ubiquitin fusion system is known to bring 
expressed proteins into soluble regions of the cell which can make purification more 
facile by using conventional methods.  Moreover, another fusion system, KSI 
(ketosteroid isomerase) was chosen and tested.  KSI is a widely used fusion system 
that promotes protein expression into inclusion bodies.  However, the desired studies, 
KSI fusion system were not able to over-express target proteins (Figure 1-4).  Very low 
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protein yields were obtained using the ubiquitin fusion system and most of the protein 
expressed was truncated.  The Trp leader proved to be the most successful at 
producing milligram quantities of full-length protein. 
To optimize the Trp leader system several conditions of Trp leader were tested.  The 
Trp leader fusion system was tested using a His-12 tag, but the protein expression 
level was low.  Repeating codons of the His-12 tag were not favorable for E.coli and 
resulted in low expression level.  The highest expression level was obtained when the 
codons were optimized and the His-tag was removed.   
Although the caveolin-1 construct only expressed well with the Trp leader fusion 
partner, the RfbP(18-51) construct expressed well with the Ubiquitin fusion partner.  
This is likely because the RfbP(18-51) construct had more soluble amino acids 
compared to the caveolin-1 constructs.  However, the Trp leader fusion system 
appeared to be most effective and reliable when expressing extreme hydrophobic 
proteins.  In addition, expression of small proteins (approximately 2 kD) can be 
enhanced by adding ubiquitin which is a well-expressing protein in E.coli following Trp 
leader.  The expression level of the Trp leader fusion protein was sufficient to obtain 
milligram quantities for NMR structural determination.  Using these methods caveolin-
1(96-136), caveolin-1(122-142), and RfbP(18-51) were successfully expressed.   
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Purification 
Optimization of inclusion body purification 
Once the protein is successfully expressed in the Trp leader fusion system, it is 
purified and isolated from the fusion protein.  Several wash steps will lead to semi-pure 
protein and cyanogen bromide cleavage will isolate the target protein by cleaving after 
a single methionine residue, which is incorporated between Trp leader and the target 
protein.  The first wash step with 20% sucrose was effective at removing most of the 
soluble proteins.  This step was optimized using different concentrations of sucrose 
and verifying the presence of protein by SDS-PAGE electrophoresis (Figure 1-7).  
Based on the experimental data, adding sucrose to the first purification step was 
effective, but the concentration of sucrose had to be optimized to use as a reliable 
method.  Therefore, different concentrations of sucrose were used and 20% sucrose 
made the buffer dense enough such that most of the unwanted proteins floated and the 
inclusion bodies pelleted.  The second wash step with 1% Triton X-100 was effective at 
removing most of the membrane proteins that are soluble in 1% Triton X-100.  The 
target protein was extremely hydrophobic and remained in the inclusion bodies.  
Several different detergents were tested such as Tween-20, Triton X-100, NP-40 and 
SDS.  Tween-20 was too mild and could not remove the soluble membrane proteins 
effectively.  The Triton X-100 was mild enough to preserve the inclusion bodies and 
wash away most of the other proteins.  The NP-40 was slightly stronger compared to 
Triton X-100 and there is some loss of the target proteins.  SDS was too strong to use 
because it dissolved the inclusion bodies.  Based on the experiments, the most 
effective and reliable detergent to purify the inclusion bodies was Triton X-100.  After 
the detergent wash step, a 60% isopropyl alcohol (IPA) wash was performed to remove 
Triton X-100 effectively by increasing the critical micelle concentration.  The remaining 
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inclusion body pellet was dissolved in 88% formic acid for cyanogen bromide cleavage.  
Using this method caveolin-1(96-136), caveolin-1(82-136), and RfbP was successfully 
purified. 
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Figure 1-7.  SDS-PAGE gel of sucrose concentration test.  Lanes 1 and 10 is the MW
ladder; lanes 2 and 3 are pre/post centrifugation in 20 mM Tris, 0.5 M sucrose, pH 8;
lanes 4 and 5 are pre/post centrifugation in 20 mM Tris, 0.7 M sucrose, pH 8; lanes 6
and 7 are pre/post centrifugation in 20 mM Tris, 0.9M sucrose, pH 8; lanes 8 and 9
are pre/post centrifugation in 20 mM Tris, 1.1 M sucrose, pH 8; lanes 11 and 12 are
pre/post centrifugation in 20 mM Tris, 1.3 M sucrose, pH 8; lanes 13 and 14 are
pre/post centrifugation in 20 mM Tris, 1.5 M sucrose, pH 8.  
1 2 3 4 5 6 7 8 9 10 11 12 13 14
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Ubiquitin_RfbP 
Purification of the RfbP(18-51) construct with the ubiquitin fusion partner was 
performed using Ni-NTA affinity chromatography.  However, the protein was not 
soluble in 8 M Urea or 6 M GuHCl buffer alone but with aid of 0.1% SDS it was soluble 
in the buffer system.  However, the problem with this method was that the Ni-NTA 
column has minimal compatibility with SDS detergent can solubilize the target protein.  
Therefore, other mild detergents were tested to find the optimal detergent that is 
soluble and compatible with Ni-NTA affinity column.  Mild detergents such as Tween-
20 or Triton X-100 were not powerful enough.  Therefore, 0.1% SDS with 8 M urea was 
used to solubilize the protein and load the column.  The column was washed using 
buffer containing 250 mM imidazole, 0.1% SDS and 8 M Urea.  After purification SDS 
cannot be completely reomoved.  Therefore, we were not able to find an optimal 
cleavage method to isolate the target protein.   
Purification using PFOA 
Small hydrophobic proteins such as caveolin-1(122-142) were not able to be 
purified using the established inclusion body purification method.  The extinction 
coefficient of the small peptide is very low and difficult to detect compared to the 
impurities.  Although it looks pure in the SDS-PAGE electrophoresis gel, there are still 
traces of unwanted proteins that strongly absorb in the reverse phase HPLC at a 
wavelength of 280 nm.  Therefore, a more effective purification step is required to 
isolate the desired protein.  After over-expressing the caveolin-1(122-142) hydrophobic 
peptide, it needed to be solubilized.  Because integral membrane proteins are usually 
very hydrophobic, they do not dissolve in aqueous buffers.  Therefore, detergents are 
usually used to promote solubilization of membrane proteins.  In many cases, common 
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detergents such as Triton X-100, NP-40, and Tween-20 are successful in dissolving 
hydrophobic proteins.  On the other hand, integral membrane proteins are among the 
most hydrophobic and traditional detergents are not strong enough to solubilize these 
proteins.  For that reason, the addition of 0.1% SDS with a chaotropic agent such as 8 
M urea can be used as an alternative to reconstitute highly insoluble proteins.  
However, there are disadvantages associated with the use of SDS.  For example, SDS 
is difficult to remove after purification and it is minimally compatible with nickel affinity 
chromatography.  Therefore, using nickel affinity chromatography was of limited utility 
in purifying highly insoluble proteins, since these proteins are not soluble in 8 M urea or 
6 M Gu-HCl, and they are only slightly soluble in low concentrations of SDS.  Higher 
concentrations of SDS are not compatible with the nickel resin.  Membrane proteins 
also dissolve particularly well in strong organic acids or highly fluorinated solvents like 
trifluoroethanol (TFE) or hexafluoroisopropanol (HFIP), but these solvents are not 
compatible with the nickel resin.  The fluorinated detergent, pentadecafluorooctanoic 
acid (PFOA), is very effective at solubilizing extremely hydrophobic proteins at neutral 
pH.  Also, this fluorinated compound is completely compatible with nickel affinity 
chromatography according to Bear et al (60).  Since PFOA is compatible with nickel 
affinity chromatography, only two wash steps are required to semi-purify the inclusion 
bodies.  Thus, we designed our purification system for small proteins with two inclusion 
body washes: wash 1 to remove the bulk of soluble proteins and wash 2 to remove the 
semi-hydrophobic membrane proteins that are still soluble in Triton x-100 detergent 
buffer.  After two wash steps and nickel affinity chromatography, the isolated full-length 
fusion protein was obtained.  Based on the results of the inclusion body preparation, 
the SDS-PAGE gel shows relatively pure material that has a MW (molecular weight) of 
approximately 25 kD.  Therefore, the washes appear to very effective in removing 
many undesirable proteins from the fusion protein.  Also, after the nickel column, the 
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elution of the fusion protein looks relatively pure (Figure 1-8).  Our optimized construct 
was designed with eight histidines in front of Trp leader protein for nickel affinity 
purification steps with PFOA.  Furthermore, we substituted an elution buffer containing 
imidazole at a pH of 8 for a low pH buffer, which we found to improve peak sharpness 
dramatically.  Lastly, we found that the position of the His-tag affects the binding of the 
protein to the nickel affinity column.  The N-terminal octa-histidine tag appears to 
provide optimal binding of our fusion protein to the nickel resin.  Once target protein 
was eluted, PFOA was removed by extensive dialysis with buffer exchange every day.   
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Figure 1-8.  SDS-PAGE gel of Trp leader-ubiquitin-M-caveolin-1(122-142).  Lane 1 is 
MW ladder; lane 2 and 3 is pre/post centrifugation in 20 mM Tris, 20% (w/v) sucrose, 
pH 8; lane 4 and 5 is pre/post centrifugation in 20 mM Tris, 1% Triton X-100, pH 8; 
lane 6 is post centrifugation in 25 mM phosphate, 8% PFOA, pH s8; lane 7 is 
flowthrough from Ni-NTA affinity column; lane 8 is wash with 25 mM phosphate, 1%
PFOA, pH 8; and lane 9 is elution with 3 mM acetate, 1% PFOA, pH 4.  
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Cleavage method. 
A variety of enzymatic and chemical cleavage methods were tested to figure 
out the best cleavage method.  The enzymatic cleavage method such as TEV or 
Thrombin was not compatible with the detergent buffer or high concentration of urea 
buffer.  The enzymes were denatured and were not able to the cleave target protein 
form the fusion protein.  Thus we tried to exchange buffers that are optimized to 
enzyme use with an amicon ultra concentrator.  However, the protein was precipitating 
out as soon as the buffers were exchanged.  Therefore, the buffer exchange was 
performed while the protein was bound to Ni-NTA resin.  But this method was not 
reliable, whenever we performed buffer exchange step lead to precipitation of protein.  
Although we can cleave the target protein, it precipitated out inside the resin and only 
the fusion partner was isolated.  The target protein was precipitated inside the resin 
and we were never able to re-dissolve and isolate them.  The membrane proteins are 
mostly hydrophobic residues which promotes aggregation without detergents.  
Therefore, we adopted an inclusion body purification method and tried other chemical 
cleavage methods.  Hydroxylamine was the other choice instead of cyanogen bromide 
cleavage.  The drawback of cyanogen bromide cleavage was it cleaves after 
methionine residues making the mutation of construct necessary if construct does not 
contain methionine.  The hydroxyl amine cleavage method cleaves between Asn and 
Gly residues (61, 62).  It is unlikely to have Asn-Gly sequence in the transmembrane 
domain since Asn is not very hydrophobic.  The full length fusion protein was semi 
purified using an inclusion body purification method and then subjected to hydroxyl 
amine cleavage.  The problem with this cleavage method was the buffer condition was 
basic and not able to solubilize proteins.  Therefore we also adjusted buffer conditions 
by adding detergent into the buffer however the reaction did not proceed well with 
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detergents around.  The yield of this cleavage method was less than 30% not enough 
for structural studies.  Thus, we adopted the cyanogen bromide cleavage method 
which was able to get close to 100% completion of the cleavage products.  Therefore, 
the cyanogen bromide cleavage method was performed to separate the target protein 
from the fusion partner.  Because membrane proteins are particularly soluble in organic 
acids, 70%-88% formic acid was used as the reaction medium.  Formic acid is well 
suited for the cyanogen bromide cleavage because it provides a highly acidic medium 
required for successful cleavage.  Alternatively, trifluoroacetic acid (TFA) or 
hydrochloric acid (HCl) solution can also be used.  However, formic acid proved to be 
the most effective at cleaving hydrophobic proteins from fusion proteins in large scale 
preparations.  The drawback to using cyanogen bromide is that all native methionine 
residues in a membrane protein sequence must be mutated.  Therefore, a hydrophobic 
protein that contains several methionine residues in its native sequence, may have to 
utilize an alternative cleavage method.  However, other cleavage buffer conditions 
were not compatible with this hydrophobic protein.  Moreover, the enzymetic cleavage 
method in PFOA buffer was inactive because PFOA denatures enzyme.  The target 
proteins were effectively separated from the fusion partner using the cyanogen 
bromide method.   
Separation and Verification 
After cleaving the target protein from its fusion partner, the protein is separated 
using C4 reverse phase HPLC.  Up to date, typically proteins are purified using a 
standard reverse-phase C18 column with a water/acetonitrile gradient with 0.1% 
trifluoroacetic acid.  However, due to the hydrophobicity of our protein, we used a C4 
column instead of longer carbon chain columns to prevent the hydrophobic protein 
from binding very tightly on the column.  Moreover, the conventional buffer conditions 
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such as water / acetonitrile gradient to separate proteins was not able to be used in this 
case because those conditions were not strong enough to elute our target protein.  
Instead of the typical method, the gradient system from 80% water/20% acetic acid to 
80% 1-butanol/20% acetic acid was used.  The 20% acetic acid was critical to mix the 
two buffer and butanol buffer was strong enough to elute very hydrophobic proteins.  
Usually 1%/min gradient was used to isolate the target protein and elution is usually 
around 35% of buffer with butanol.  To prevent aggregation of the target protein, it is 
critical to redissolve the protein in 88% formic acid immediately before loading it onto 
the column.  The HPLC spectrum of the cyanogen bromide reaction shows three major 
peaks (Figure 1-9).  The first peak is formic acid; the second large and somewhat 
broad peak represents the cleaved fusion partner portion of the fusion protein.  The last 
peak in the spectrum represents the cleaved target protein.  We expect the target 
protein to elute last due to the fact that it is more hydrophobic than the fusion partner.  
Moreover, nickel chromatography was critical to obtain pure protein for caveolin-1(122-
142) based on HPLC trace comparison.  Executing extra inclusion body washes was 
not helpful to the purity of the protein on the HPLC trace.  Although SDS-PAGE gel 
looks clean after two inclusion body washes, it was unable to verify the protein peak in 
HPLC.  Our results are confirmed by MALDI-TOF mass spectrometry (Figure 1-10).  
Most of the spectra were obtained using reflectron positive ion mode.  For small 
proteins, such as caveolin-1(122-142), α-cyano-4-hydroxycinnamic acid was used as 
the matrix.  A mono isotopic molecular weight of Caveolin-1(122-142) is small enough 
to obtain high resolution spectra.  It was also possible to detect different isotopic peaks 
along with sodium and formate adducts of caveolin-1(122-142).  The MALDI-TOF 
spectrum confirms that caveolin-1(122-142) was successfully separated from the 
fusion protein.  For 4kD to 6kD proteins, sinapinic acid is used as the matrix and the 
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spectra were obtained with high resolution that was able to detect sodium and formate.  
This confirms that the target protein is successfully isolated.  After verification by 
MALDI mass spectroscopy proteins are dried down with SpeedVac and redissolved 
into HFIP and lyophilized for further usage.  HFIP is often used to deaggregate 
membrane proteins and is the only organic solvent that will dissolve extremely 
hydrophobic proteins and will lyophilize nicely.   
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Figure 1-9.  C4 reverse phase HPLC.  Target protein is isolated from the fusion
protein at flow rate 10 mL/min using buffer condition 20% acetic acid 80% water to
20% acetic acid 80% butanol.  a) Purification of caveolin-1(96-136) using 1%/min
gradient.  b) First purification of caveolin-1(122-142) using 0.8%/min gradient. c)
Second purification of caveolin-1(122-142) using 0.8%/min.  
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Conclusion 
Although a lot of challenges remain in the field of membrane proteins, our hope 
is that the method outlined here will serve as an aid to those who wish to obtain highly 
insoluble proteins for membrane protein studies.  It is our belief that the Trp leader 
fusion expression system could be a universal method to produce high yields of small 
membrane proteins.  Moreover, this method could potentially replace the highly 
expensive solid-phase protein synthesis method.  Currently, the only drawback to the 
method at hand is that it relies on the cyanogen bromide method of cleavage, which 
requires that all methionine residues in the native protein sequence be mutated to 
avoid truncation of the desired protein.  It may be desirable to investigate additional 
cleavage methods for proteins that contain native methionine residues in their primary 
structure.   
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Appendix 1-1.  Design of oligomers 
Caveolin-1(96-136) 
5’ oligomer 
CGCGGATCCATGAAATACTGGTTCTACCGTCTGCTGTCTGC
GCTGTTCGGTATCCCGCTGGCGCTGATCTGGGGTATCTAC
TTCGC 
3’ oligomer 
CCGGAATTCTCAAGATTTGATAGACGGAACAACCGCCCAG
ATGTGCAGGAAAGACAGGATCGCGAAGTAGATACCCCAGA
TCAGCG 
Caveolin-1(122-142) 
5’ oligomer CGCGGATCCATGCTGTCTTTCCTGCACATCTG 
3’ oligomer CCGGAATTCTTACTGGATTTCGATCAGGAAAG 
RfbP 
5’ oligomer 
CGCGGATCCATGCGTTTCCTGAAACGTACCTTCGACATCGT
TTCTTCTATCATCATCCTGATCATCGCGTCTCCGC 
3’ oligomer 
CCGGAATTCTCAACCGTCACGGGTAACTTTGTACCACAGGT
AGATCAGCAGCGGAGACGCGATGATCAGGATGAT 
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Appendix 1-2.  PCR cycle for the synthetic preparation. 
1 cycle 95ºC 2 minutes 
5 cycles 
95ºC 15 seconds 
45ºC 15 seconds 
72ºC 1 minute 
1 cycle 72ºC 5 minutes 
 4ºC  
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Appendix 1-3.  Transformation Protocol (XL-1 blue) 
1. Take 50 µL of cells from -80ºC freezer and thaw on ice 
2. Put competent cells into pre-chilled 15 mL culture tubes 
3. Add 1 µL of ligation reaction mixture 
4. Keep in the ice for 30 minutes 
5. Heat shock at 42ºC for 90 seconds 
6. Keep in the ice for 2 minutes 
7. Add 400 µL S.O.C. 
8. Incubate at 37ºC for 1 hour at shaking speed 225 rpm. 
9. Pour into LB plate with Kanamycin. 
10. Incubate overnight at 37ºC 
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Appendix 1-4.  Transformation Protocol (BL21(DE3)) 
1. Take 50 µL of cells from -80ºC freezer and thaw on ice 
2. Put competent cells into pre-chilled 15 mL culture tubes 
3. Add 20 ng of DNA 
4. Keep in the ice for 30 minutes 
5. Heat shock at 42ºC for 90 seconds 
6. Keep in the ice for 2 minutes 
7. Add 400 µL S.O.C. 
8. Incubate at 37ºC for 1 hour at shaking speed 225 rpm. 
9. Pour into LB plate with Kanamycin. 
10. Incubate overnight at 37ºC 
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Appendix 1-5. Reagents for media preparation 
ZYM-5052 (2 Liters) N-5052 (2 Liters) 
1916 mL H2O 
20 grams NZ-Amine AS 
10 grams Yeast Extract 
4mL MgSO4 
400 µL 1000X Trace Metal 
40 mL 50X5052 
40 mL 50XM 
 
14.196 grams Na2HPO4 
13.609 grams KH2PO4 
1.42 grams Na2SO4 
1956 mL H2O 
5.45 grams 15NH4Cl 
4mL MgSO4 
400 µL 1000X Trace Metal 
40 mL 50X 5052 
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Appendix 1-6.  Reagents for starter preparation 
MDAG (5 mL) 
4.46 mL H2O 
10 µL MgSO4 
1 µL 1000X Trace Metal 
50 µL 25% Aspartate 
100 µL 50XM 
62.5 µL 40% Glucose 
100 µL 17 Amino Acids 
40 µL Methionine 
5 µL Kanamycin (or appropriate antibiotic) 
A tip of stock freeze 
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Chapter 2. Caveolin-1 transmembrane domain 
Abstract 
Caveolin is an integral membrane protein that is found in high abundance in 
caveolae.  Caveolin possesses an unusual horseshoe topology in the membrane which 
is thought to facilitate its many functions.  In particular, a conserved proline residue 
(P110) in the caveolin transmembrane domain appears to be critical for proper 
orientation.  To study the effects of this important residue, we have prepared a 
construct of the caveolin protein that encompasses the intact transmembrane domain 
(96-136).  Caveolin (96-136) was over-expressed and isotopically labeled in E.coli, 
purified to homogeneity, and incorporated into lyso-myristoylphosphatidylglycerol 
micelles.  Circular dichroism spectroscopy reveals that the secondary structure of 
caveolin (96-136) contains mostly α-helical character.  Furthermore, NMR 
spectroscopy reveals that the transmembrane domain is composed of a helix-break-
helix motif which allows caveolin to adopt it’s unique conformation.  Also, alanine 
scanning was carried out to probe the structural significance of residues 108-110 which 
create the helix-break in the transmembrane domain.  Results indicate that position 
108 requires small side chain amino acids, position 109 requires β-branched amino 
acids, and postion 110 requires proline.  This research will ultimately lead to the 
elucidation of three-dimensional structure of caveolin on an atomic level. 
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Introduction 
The most distinguishing feature of caveolin is that both the N- and C- termini 
are located on the same side of the plasma membrane (20, 23).  This unusual topology 
is supported by a variety of in vivo studies which include immunofluoresence, 
immunoelectron microscopy, and epitope mapping (20, 23, 63, 64, 65).  In addition, 
based on hydropathy prediction the transmembrane domain is approximately 33 
residues (residues 102 to 135).  The length of the transmembrane domain is unusual 
because it is too long to span the transmembrane domain once and too short to span 
twice.  Combination of these studies have led to the postulation that the 
transmembrane domain forms a unique horseshoe structure in the membrane (turn 
inside of membrane).   
Previous studies on caveolin-1 were carried out in vivo, but there are few 
biophysical studies on caveolin-1 particularly few on the transmembrane domain.  
Furthermore, there is no direct evidence to confirm the unique horseshoe conformation 
of caveolin-1 in the membrane at the molecular level.  Without knowing the structure of 
the protein at the molecular level it is difficult to understand the role that caveolin-1 
plays.  Therefore, it is critical to determine the three-dimensional structure of caveolin-1 
in lipid bilayers as this information will enhance future studies. 
Interestingly, in the transmembrane domain of caveolin, two conserved proline 
residues (P110 and P132) appear to be critical for proper biological function.  For 
example, a point mutation of proline at residue 132 to leucine (P132L) has been 
strongly correlated with breast cancer.  In 16% of breast cancer cases, the P132L 
mutation was found in patients (27, 66, 67, 68, 69, 70, 71, 72, 73).  Also, a proline to 
alanine mutation at position 110 (P110A) showed that the N-terminus of caveolin-1 was 
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exposed to the extracellular domain instead of facing the intracellular domain which 
could mean losing horseshoe conformation (26).  Therefore, proline at position 110 
(P110) in the transmembrane domain could be a candidate for the amino acid that is 
responsible for the turn in the horseshoe conformation.  It is necessary to directly 
observe the structure of the caveolin transmembrane domain to investigate the role of 
P110.   
The intact transmembrane domain of caveolin-1(96-136) was expressed and 
purified for biophysical studies.  Pure protein was reconstituted into LMPG micellar 
solution to probe the structure by circular dichroism and NMR spectroscopy.  Circular 
dichroism data demonstrate that caveolin-1(96-136) is highly helical and NMR data 
show that transmembrane domain exhibits helix-break-helix.  These two conclusions 
imply that caveolini-1 transmembrane domain is likely responsible for the formation of 
the unique horseshoe conformation. 
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Mateial/Methods 
Expression and purification 
All mutant constructs were prepared using the modified QuikChange site-
directed mutagenesis method (Appendix 2-1, Appendix 2-2).  Reaction was performed 
with 50ng of vector which contains wild-type caveolin-1(96-136), 100ng of forward 
primer, 2.5uL of 9ºN ligase buffer, 2.5uL of 10X pfu buffer, 0.2uL of DMSO, 1.0uL of 
dNTPs, 1.0uL of pfu turbo, 1.0uL of 9ºN ligase, and bring the volume to 25uL with 
sterile water.  The thermal cycler was set to the following cycling conditions:  1 cycle at 
95 °C for 1 minute, 30 cycles at 95°C for 1 minute, 50 °C for 1 minute, 65 °C for 13 
minutes, 4 °C for an indefinite period.  Reaction products are digested with Dpn1 
overnight at room temperature and transformed into XL-1 blue subcloning grade cells.  
After sequence analysis it is transformed into BL21(DE3) cells for protein expression. 
The expression was performed with Trp leader fusion protein and purification 
was done using inclusion body purification method.  The detail protocols are described 
in expression and purification chapter.  For three-dimensional experiments, minimal 15N, 
13C-labeling is required.  To incorporate these isotopes into our protein, a cell growth 
was performed in M9 minimal media using a procedure that was optimized by Marley 
et al (58).  This protocol uses 13C glucose and 15NH4Cl as the only carbon and nitrogen 
source to label both of them.  For specific amino acid labeling, the cell growth was 
done using M9 minimal media with 5 fold excess of 14N 19 amino acids related to the 
desired 15N amino acid (59).  The growth was induced with 1 mM IPTG at O.D. 0.6 and 
grown for 6- 8 hours.  After harvesting cell same purification was done to obtain NMR 
sample. 
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Sample preparation 
To prepare a caveolin-1(96-136) NMR sample, various detergents were 
screened to determine which detergent was compatible with our sample and which 
detergent gave the best resolution in the NMR.  Some detergents were not strong 
enough to solublize caveolin-1(96-136) while others, particularly ionic detergents, were 
too strong and can denature caveolin-1(96-136). For our studies we found that LMPG 
(lysomyristoylphosphatidylglycerol) was the only detergent that was both powerful 
enough to solubilize the hydrophobic caveolin-1(96-136) and also gave a well-
dispersed HSQC spectrum.  The LMPG micellar solution was prepared with 100 mM 
LMPG, 100 mM NaCl, 20 mM phosphate, pH 7.  The NMR sample was prepared by 
dissolving 2.5mg 15N labeled caveolin-1(96-136) in approximately 500 μL of the LMPG 
micellar solution.  Vigorous vortexing and a brief heat shock were applied for effective 
sample preparation.  The peptide concentration was verified by Biospec spectrometer 
at 280 nm and an extinction coefficient of ε=20970 M-1cm-1.   
The sample used for circular dichroism studies were prepared in a similar 
manner to the NMR sample except that the protein concentration was approximately 
0.05 mM.  Therefore, the CD sample was obtained by diluting the NMR sample with 
the LMPG micellar solution after the NMR experiments were carried out.   
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CD and NMR 
All circular dichroism experiments were performed using a JASCO CD 
Spectrophotometer (Easton, MD).  The experiments were carried out at 25 ̊C. Spectra 
were obtained using step mode in the wavelength range of 260 to 190 nm using 16 
accumulations.  A background spectrum was obtained using the LMPG micellar 
solution containing no caveolin protein and was subsequently subtracted from the 
spectrum of the protein sample.  In all cases a 0.1 mm path length cuvette was used.  
The sample volume was approximately 250 µL.  The data were processed using web-
based computer program, Dichroweb (45, 46, 47). 
The HSQC spectrum of caveolin-1(96-136) in LMPG micelles was acquired at 
37°C using the TROSY-HSQC pulse sequence on a 600 MHz Bruker (Billerica, MA) 
Advance II spectrometer equipped with a cryoprobe.  The instrument is located at Penn 
State Hershey Medical College in Hershey, PA.  The spectrum was acquired with 256 
(15N dimension) × 2048 (1H dimension) complex points using a total of 16 scans. The 
data were Fourier transformed using the NMRPipe program (48).  After the HSQC 
spectrum was acquired, a series of other experiments were carried out including three-
dimensional experiments such as HNCA and HN(CO)CA to obtain detailed information 
about the backbone structure of caveolin-1(96-136).  To run the three-dimensional 
experiments 15N and 13C labeling is required.  Specific amino acid 15N labeling is also 
used to assist in assigning the resonances of the peptide backbone.  Using specific 
amino acid labeling the HSQC spectrum shows only peaks that are labeled with 15N 
amino acids.  Overlaying the specific amino acid-labeled spectrum with the uniformly 
15N-labeled spectrum allows us to confirm the identity of the peaks in the HSQC 
spectrum.  This information is used to analyze and check the backbone assignment 
made from the HNCA and HN(CO)CA experiments.  The spectra were processed 
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using NMRPipe and Sparky (45, 46, 47, 74).  Secondary structure information was 
obtained using Cα chemical shifts as described in Wishart et al (75).  Dihedral angles 
for wild-type were obtained using the computer program TALOS+ and H, N, CO, Cα, 
and Cβ chemical shift data were used (49).  After TALOS+ preliminary structures were 
built using the computer program CS-ROSETTA which build structure based on 
chemical shifts and side chain packing (76).  
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Results and Discussion 
CD 
The secondary structure of caveolin-1(96-136) was revealed using circular 
dichroism spectroscopy in LMPG detergent micelles. The LMPG micellar solution was 
chosen for consistency with other experiments because the LMPG offered the highest 
quality NMR spectrum.  The data obtained from the circular dichroism experiments was 
processed using a web-based computer program called Dichroweb, which determined 
the percent α-helicity of caveolin-1(96-136) (45, 46, 47).  The results of the Dichroweb 
analysis show that there are two minima at 208 and 222 nm which is indicative of α-
helical properties.  Analysis of the spectrum using the CDSSTR and K2D algorithms 
(Dichroweb) indicates that α-helicity of caveolin-1(96-136) is greater than 57%.  Also 
the percentage of turns in the peptide is determined to comprise approximately 10% of 
the peptide structure, which means that 3-4 amino acid residues could be found in turn 
regions of the structure.  However, mutation of proline 110 to alanine results in a 
circular dichroism spectrum that is remarkably similar to that of the wild-type.  
Therefore, mutation of proline 110 to alanine does not dramatically alter the secondary 
structure of Caveolin-1(96-136).  Also other mutations G108A and I109A show similar 
secondary structure to that of the wild-type. (Figure 2-1). 
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Figure 2-1.  a) Circular dichroism spectroscopy of caveolin-1(96-136). Using
programs in Dichroweb revealed mostly α-helical character in caveolin-1(96-136).  b)
Circular dichroism spectroscopy of caveolin-1(96-136) mutants; P110A (blue), I109A
(red), and G108A (green).   
 
 72 
NMR backbone assignment 
The wide dispersion of the HSQC spectrum in LMPG micelles suggests that 
each amino acid is surrounded by a unique environment. The caveolin-1(96-136) 
HSQC peak dispersion is greater compared to a typical single-spanning 
transmembrane alpha helix, which is not surprising because the transmembrane 
domain of caveolin has such an unusual topology.  After obtaining a high quality HSQC 
spectrum, backbone assignment is necessary to get structural information.  In order to 
assign the backbone of caveolin-1(96-136) 13C- and 15N- labeling was required.  For 
initial experiments, 13C-, 15N- labeled caveolin-1(96-136) was reconstituted into LMPG 
micelles, and an HSQC spectrum was obtained to check the signal-to-noise ratio and 
the intensity of peaks (Figure 2-2).  This step is necessary to determine if signals were 
intense enough for a series of three-dimensional experiments.  For the three-
dimensional experiments, the HNCA experiment was executed first because it is one of 
the most sensitive the three-dimensional experiments.  The HNCA experiments provide 
both intra- and inter- molecular Cα information from which the backbone of caveolin-
1(96-136) can be identified.  Intra-molecular Cα gives a strong signal while inter-
molecular Cα gives a weak signal.  By matching the strong peak of the starting peak to 
the weak peak of the other peak this approach allows us to assign the backbone of the 
protein (Figure 2-3).  Unfortunately, chemical shift degeneracy can lead to ambiguous 
backbone assignments.  Therefore, it is desirable to use additional experiments to aid 
backbone assignment.  We chose to specifically label each amino acid using the 15N 
isotope.  In the caveolin-1(96-136) protein we chose to specifically label leucine, 
isoleucine, alanine, phenylalanine, and valine each of which was carried out in five 
separate preparations of the protein.  These amino acids were chosen because leucine 
and isoleucine are the most abundant residues in the peptide which would give us the 
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most information.  Also, alanine and phenylalanine are well-dispersed throughout the 
peptide based on primary sequence analysis.  Labeling specific amino acid helps to 
provide a starting point when assigning the peaks in the HSQC spectrum (Figure 2-4, 
Figure 2-5, Figure 2-6).  Initially, 15N labeled glycine was used as a starting point in 
assigning chemical shifts because it gives a unique chemical shift in the HSQC 
spectrum compared to the other amino acids.  Therefore, without specific labeling 
glycine would be the only known starting points which would make backbone 
assignment very difficult.  Also knowing which peak represents which amino acid, it is 
very useful to verify that the direction of the backbone assignment is correct.  Also 
HN(CO)CA experiment was performed to help backbone assignment.  This experiment 
only provides inter Cα values which can be compared to HNCA experiment and help 
identifying inter and intra Cα peaks.  Moreover, HNCO and HNCACB experiments are 
executed to obtain Cβ and CO information.  The HNCACB information helps identifying 
threonine, serine and alanine because chemical shifts of Cβ are unique compare to 
other amino acids.  The HNCO experiment is one of the most sensitive three 
dimensional experiments along with HNCA.  These experiments are helpful to verify 
ambiguous peaks.   
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Figure 2-2.  1H-15N TROSY-HSQC spectrum of uniformly 1H- and 15N-labeled 
caveolin-1(96-136) in 100 mM LMPG, 100 mM NaCl, 20mM Phosphate pH 7.  The 
spectrum was recorded at 37ºC on a 600 MHz spectrometer with 256 complex points
in t1, 2048 complex points in t2. 
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Figure 2-3.  Walk through of backbone assignment of caveolin-1(96-136) using strips 
of HNCA experiment. 
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Figure 2-4.  1H-15N TROSY-HSQC spectrum of alaine specific 15N-labeled caveolin-
1(96-136) in 100 mM LMPG, 100 mM NaCl, 20mM Phosphate pH 7.  The spectrum 
was recorded at 37ºC on a 600 MHz spectrometer with 256 complex points in t1,
2048 complex points in t2. 
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Figure 2-5.  Overlay of 1H-15N TROSY-HSQC spectrum of alaine specific 15N-labeled 
caveolin-1(96-136) (Red) and uniformly 15N-labeled Caveolin-1(96-136) (Blue). 
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Figure 2-6.  Overlay of 1H-15N TROSY-HSQC spectrum uniformly 15N-labeled
caveolin-1(96-136)  with specific 15N-labeled  caveolin-1(96-136); Phe (yellow), Leu
(green), Ala (purple), Ile (orange), Val (pink). 
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Analysis of CSI 
After obtaining Cα information of all the peaks, their chemical shifts were 
indexed (CSI).  The chemical shift index analyzes the differences between the 
chemical shifts of the Cα of each amino acid in the structure of the protein versus the 
chemical shift given by the same amino acid from a random coil structure.  If the Cα is 
positive, it represents α-helica character and if Cα is negative it represents β-sheet 
character.  But for both cases, a series of Cα has to be consecutive to represent 
secondary structure.  In other words, if two or three amino acids Cα is positive or 
negative it does not represent secondary structure.  After processing all of the residues, 
a helix-break-helix motif was found in the transmembrane domain of caveolin-1 (Figure 
2-7).  The first helix starts at Tyr97 and ends at Phe107 because the Cα’s are all 
positive.  The second helix starts at Leu111 and ends at Ala129 because the Cα’s are 
positive.  The breakage between these two helices spans Gly108 to Pro110 because 
Cα is negative but it is not enough to say there is a β-sheet.  The remaining amino 
acid residues are situated toward each of the ends of the peptide and they are not well 
structured.  The C-terminal region is a dynamic portion of this protein.  Therefore, 
Gly108, Ile109, and Pro110 are potential turn point for the unusual horseshoe structure 
because these amino acids are located at a critical place in the transmembrane 
domain and create a break in the helical structure.  This is the first experimental data 
presented of a helix-break-helix motif in the caveolin-1 transmembrane domain.  
Moreover, potential candidates for the critical amino acids responsible the for 
horseshoe conformation were revealed.  This data is verified by the TALOS+ computer 
program which is a program that can estimate torsion angles based on chemical shifts 
(49).  This program was used to obtain the torsion angle phi (φ) and psi (ψ) of caveolin-
1(96-136), both of which are necessary for the three-dimensional structure of caveolin-
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1(96-136).  When the N, H, CO, Cα, and Cβ chemical shifts for the caveolin-1(96-136) 
were entered into the computer program TALOS+, residues Y97–V131 were 
confidently predicted to have dihedral angles and residues P132–K135 were predicted 
to be dynamic.  This information can then be entered into a program called CS-Rosetta 
(76, 77).  This program is a powerful tool that is used to build a protein structure using 
all of the detailed information provided by the experiments performed herein.  CS-
Rosetta, the program generates a series of possible structural models all of which 
satisfy the torsion angles specified, the proper bond length and van der Waals contact 
of the amino acid residues, and lowest energy states as it relates to the side chain 
packing of the residues.  The data generated from CS-Rosetta can be subsequently 
visualized using XPLOR (NIH) where further refinements to the structure can also be 
made (Figure 2-8) (78, 79).   
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Figure 2-7.  Chemical shift indexing of caveolin-1(96-136).  Caveolin-1(96-136) 
displays a helix–break–helix structure.  Red highlight denotes breakage region and 
green highlights denotes dynamic region. 
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Figure 2-8.  Model of Caveolin-1(96-136) created by CS-ROSETTA and visualized by 
X-PLOR.  
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Alanine Scanning 
Alanine scanning is often carried out to determine the contribution of a specific 
amino acid to the protein structure and function.  Alanine is usually selected because it 
has a relatively small and hence neutral side chain.  Three residues are of particular 
interest; G108, I109, and P110, which we hypothesize to be responsible for the break 
in the structure of caveolin-1 transmembrane domain, which was revealed by CSI.  
Therefore, mutations to alanine were introduced at position 108, 109, and 110 in 
separate protein preparations and the effect on the NMR structure of these mutations 
was assessed.  Moreover, F107 was also mutated to alanine and investigated since 
the dihedral angle created by TALOS+ is not exactly an α-helix dihedral angle.  The 
alanine mutations were achieved by using a modified Quikchange site-directed 
mutagenesis protocol (Agilent Tech) and a large-scale growth was carried out following 
the procedure outlined in the previous chapter.  Overlaying the F107A HSQC spectrum 
with the wild-type HSQC spectrum shows that most of peaks overlap (Figure 2-9).  This 
suggests that the structure of the F107 mutation is similar to the wild-type.  Also 
overlaying the G108A HSQC spectrum with the wild-type HSQC spectrum shows that 
most of the peaks overlap but the residues surrounding position 108 are slightly shifted 
(Figure 2-10, Figure 2-11).  For example, residues surrounding G108 (F107 and I109) 
had slightly shifted chemical shifts but the V130 which is far away from G108 remained 
unchanged.  The G108A mutation created small changes around residue 108 but 
overall the conformation was same.  This result suggests that even though glycine has 
a small side chain (-H) this site can tolerate the bulkiness of the methyl group side 
chain introduced by the alanine.  On the other hand, the I109A and P110A HSQC 
spectra looked drastically different compared to the wild-type spectrum.  The I109A 
and P110A mutation appeared to change the overall conformation (Figure 2-12, Figure 
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2-13).  Therefore, a β-branched bulky side chain like that of isoleucine appears to be 
critical at position 109.  It may be that the alanine side chain is too small to maintain the 
structure because of loss of steric hindrance.  Also, P110A mutation was not able to 
keep native conformation (Figure 2-14, Figure 2-15).  Proline is unique due to its 
conformational rigidity.  It is not surprising that by breaking this rigidity by inserting an 
alanine at the P110 position results in a loss of the native structure.  Further analysis of 
the HSQC spectrum suggests two possible explanations, one is the loss of the native 
conformation and the other is that aggregation may be occurring.  Aggregation is not 
an event that occurs randomly in a well-structured peptide.  For aggregation to take 
place, a loss in native conformation must occur first.  Therefore, it is more likely that the 
I109A and P110A mutations cause a conformational change that results in a loss of the 
horseshoe structure thereby promoting aggregation.  To probe the details surrounding 
this phenomenon, specific point mutations were carried out at these three positions.  
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Figure 2-9.  Overlay of 1H-15N TROSY-HSQC spectra of uniformly 1H- and 15N-
labeled caveolin-1(96-136) wild-type (red) and caveolin-1(96-136)F107A mutant
(blue). 
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Figure 2-10.  1H-15N TROSY-HSQC spectrum of uniformly 1H- and 15N-labeled
caveolin-1(96-136)G108A mutant. 
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Figure 2-11.  Overlay of 1H-15N TROSY-HSQC spectra of uniformly 1H- and 15N-
labeled caveolin-1(96-136) wild-type (blue) and caveolin-1(96-136)G108A mutant 
(red). 
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Figure 2-12.  1H-15N TROSY-HSQC spectrum of uniformly 1H- and 15N-labeled 
caveolin-1(96-136)I109A mutant. 
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Figure 2-13.  Overlay of 1H-15N TROSY-HSQC spectra of uniformly 1H- and 15N-
labeled caveolin-1(96-136) wild-type (blue) and caveolin-1(96-136)I109A mutant 
(red). 
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Figure 2-14.  1H-15N TROSY-HSQC spectrum of uniformly 1H- and 15N-labeled 
caveolin-1(96-136)P110A mutant. 
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Figure 2-15.  Overlay of 1H-15N TROSY-HSQC spectra of uniformly 1H- and 15N-
labeled caveolin-1(96-136) wild-type (blue) and caveolin-1(96-136)P110A mutant 
(red). 
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Point Mutation 
To probe the nature of the side chains at positions 108-110 specific point 
mutations were introduced similar to the alanine scanning approach.  The glycine at 
position 108 (G108) was mutated to leucine and isoleucine to observe the limits of the 
side chain bulkiness and also to investigate the β-branched side chain effects.  The 
isoleucine at position 109 (I109) was mutated to leucine and valine to determine if the 
β-branched side chain is critical at position 109 or if simply the bulky side chain is 
necessary.  The proline at position 110 (P110) was mutated to glycine because glycine 
has the most conformational freedom.  Glycine has the ability to adopt a similar angle 
to that of proline, which would suggest that the peptide would still be able to maintain 
its native conformation.   
The overlay of the G108L and G108I to wild-type spectrum show that both 
result in a loss of conformation (Figure 2-16, Figure 2-17).  Therefore, at position 108 
leucine and isoleucine are not tolerated.  The limits of the bulkiness of the amino acid 
side chain revealed that only a proton or a methyl group are tolerated.  Therefore at 
position 108, glycine and alanine are the only two amino acids that are tolerated.   
At position 109, leucine appeared to be meta-stable while valine was stable 
(Figure 2-18, Figure 2-19, Figure 2-20).  This was evident by the fact that both I109L 
and I109V gave reasonable spectra but over time the leucine HSQC spectrum 
resolution was lost (Figure 2-19).  The I109L spectrum was well overlapped with the 
wild-type spectrum but several new peaks were observed which was indicative of 
meta-stable state.  The I109V spectrum was very similar to the G108A spectrum with a 
small shift around position 109, but the overall spectrum was unchanged.  Therefore, it 
appears that it is essential that a β-branched side chain be present to preserve the 
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structure and it is not simply a matter of introducing steric bulk at this position to 
stabilize the structure.  Beta-branched side chain amino acids are required at position 
109 to sustain the structure because a beta-branch is closer to backbone of the protein 
which creates more rigidity that is required to maintain unique putative turn 
conformation.   
At position 110, glycine was not able to maintain the structure (Figure 2-21).  
Specific peaks in the spectrum were not distinguishable.  The P110G spectrum was 
similar to the P110A spectrum, which suggests a loss in conformation.  Although 
glycine has the conformational freedom to adopt a similar angle to that of proline, it 
was not stable enough to maintain that angle.  Therefore, glycine may be too flexible to 
maintain one conformation which means that proline is most likely the only amino acid 
that can be tolerated at position 110.   
The conclusions of the point mutation study are that position 108 requires a 
small side chain amino acid residue such as glycine and alanine, β-branched amino 
acids like isoleucine and valine are required at position 109, and proline is likely the 
only amino acid that can be at position 110.   
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Figure 2-16.  1H-15N TROSY-HSQC spectrum of uniformly 1H- and 15N-labeled
caveolin-1(96-136)G108I mutant. 
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Figure 2-17.  1H-15N TROSY-HSQC spectrum of uniformly 1H- and 15N-labeled
caveolin-1(96-136)G108L mutant. 
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Figure 2-18.  Overlay of 1H-15N TROSY-HSQC spectra of uniformly 1H- and 15N-
labeled Caveolin-1(96-136) wild-type (red) and Caveolin-1(96-136)I109L mutant
(blue).   
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Figure 2-19.  1H-15N TROSY-HSQC spectrum of uniformly 1H- and 15N-labeled
caveolin-1(96-136)I109L mutant after 1 week. 
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Figure 2-20.  Overlay of 1H-15N TROSY-HSQC spectra of uniformly 1H- and 15N-
labeled caveolin-1(96-136) wild-type (red) and caveolin-1(96-136)I109V mutant
(blue). 
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Figure 2-21.  Overlay of 1H-15N TROSY-HSQC spectra of uniformly 1H- and 15N-
labeled Caveolin-1(96-136) wild-type (red) and Caveolin-1(96-136)I109V mutant
(blue). 
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Conclusion 
Caveolin misregulation has been implicated in many different diseases 
including cancer, Alzheimer’s disease, and muscular dystrophy.  However, there are 
few biophysical studies that have probed the structure of this protein, which is not 
surprising given the extreme hydrophobicity of this integral membrane protein. Using 
LMPG detergent micelles we have utilized techniques such as circular dichroism and 
solution NMR to study the characteristics of the caveolin-1(96-136) structure which has 
never been done for caveolin before.  Based on this data we have found that in 
addition to proline at position 110, two other residues are critical for the helix-break-
helix motif observed in this protein.   Glycine 108 and isoleucine 109 are also critical for 
the structure.  Additional NMR experiments also reveal that glycine and alanine are 
tolerable at position 108, β-branched amino acids like valine and isoleucine are 
required at position 109 and proline is essential at position 110.  This helix-break-helix 
motif is the first critical structural data of the caveolin-1 transmembrane domain that is 
based on experimental data.  This finding will bring us close to elucidating the entire 
three-dimensional structure of caveolin-1 on an atomic level.  In addition, this structural 
information will allow us to begin to answer questions about the role that this 
membrane protein plays in the cell, and how it creates the scaffold that causes 
membrane curvature.   Moreover, we hope that these studies will provide a useful 
platform from which more structural studies on other membrane proteins can be 
accomplished.  Ultimately, these studies will greatly advance the field of membrane 
protein science and will allow scientists to target these proteins for possible therapeutic 
intervention. 
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Appendix 2-1 Primers for point mutation 
P110A GCTGTTCGGTATCGCGCTGGCGCTGAT 
I109A CTGTCTGCGCTGTTCGGTGCGCCGCTGCGCCTGATCTG 
G108A CTGTCTGCGCTGTTCGCGATCCCGCTGGCGCTG 
F107A CTGTCTGCGCTGGCGGGTATCCCGCTGG 
G108I GTCTGCGCTGTTCATCATCCCGCTGGCGC 
G108L GTCTGCGCTGTTCCTGATCCCGCTGGCGC 
I109V CTGCGCTGTTCGGTGTTCCGCTGGCGCTGATC 
I109L CTGCGCTGTTCGGTCTGCCGCTGGCGCTGATC 
P110G CGCTGTTCGGTATCGGCCTGGCGCTGATCTG 
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Appendix 2-2. Protein constructs for mutation studies. 
Caveolin-1(96-136) 
M111LC133S 
KYWFYRLLSALFGIPLALIWGIYFAILSFLHIWAVVPSIKS 
Caveolin-1(96-136) 
M111LC133SG108A 
KYWFYRLLSALFAIPLALIWGIYFAILSFLHIWAVVPSIKS 
Caveolin-1(96-136) 
M111LC133SI109A 
KYWFYRLLSALFGAPLALIWGIYFAILSFLHIWAVVPSIKS 
Caveolin-1(96-136) 
M111LC133SP110A 
KYWFYRLLSALFGIALALIWGIYFAILSFLHIWAVVPSIKS 
Caveolin-1(96-136) 
M111LC133SG108L 
KYWFYRLLSALFLIPLALIWGIYFAILSFLHIWAVVPSIKS 
Caveolin-1(96-136) 
M111LC133SG108I 
KYWFYRLLSALFIIPLALIWGIYFAILSFLHIWAVVPSIKS 
Caveolin-1(96-136) 
M111LC133SI109L 
KYWFYRLLSALFGLPLALIWGIYFAILSFLHIWAVVPSIKS 
Caveolin-1(96-136) 
M111LC133SI109V 
KYWFYRLLSALFGVPLALIWGIYFAILSFLHIWAVVPSIKS 
Caveolin-1(96-136) 
M111LC133SP110G 
KYWFYRLLSALFGIGLALIWGIYFAILSFLHIWAVVPSIKS 
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Chapter 3. Probing Caveolin-1(96-136)P132L 
Abstract 
Caveolin-1 contains two highly conserved proline residues within the 
transmembrane domain at positions 110 and 132.  It has been shown that the proline 
at position at 110 is critical for the formation of horseshoe conformation.  A mutation at 
the position of the other highly conserved proline (132) to leucine has been shown to 
be involved with breast cancer pathogenesis.  Previous studies show that P132L 
mutant retained in the Golgi, which is indicative of misfunction, but there are no studies 
that investigate this mutation in atomic detail.  We utilized NMR spectroscopy 
methodologies to find differences between caveolin-1 WT and the P132L mutant on the 
atomic level.  The Trp leader fusion over-expression system was adopted and the 
purification was carried out by isolating the inclusion bodies of the WT and P132L 
fusion to obtain pure caveolin-1 constructs; caveolin-1(96-136), caveolin-1(122-142), 
and caveolin-1(62-178).  The pure protein was reconstituted into a detergent micellar 
solution (DPC, and LMPG) and was subjected to various NMR experiments such as 
HSQC, HNCA, HN(CO)CA.  The HSQC data of caveolin-1(96-136)P132L suggests 
that there is a line broadening of the peaks compared to WT caveolin-1(96-136).  
Furthermore, chemical shift indexing suggested that 4 additional amino acids were 
included in helix-2 compared to the WT protein.  Although there are 4 extra amino acid 
extension the helix-break-helix motif was still preserved in the mutant.  These data 
suggest that the caveolin-1 P132L mutant is local conformational change and not 
global conformational change.  The findings in this study will lead us to a better 
understanding of caveolin-1 P132L mutation and its role in the metastasis of breast 
cancer.   
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Introduction 
Caveolin is an intergral membrane protein that is essential to form caveolae 
which are invaginations in cell membrane (23, 24).  The loss of caveolin expression 
leads the to loss of caveolae formation and this leads to disease states as caveolae 
are a major hub of cell signaling activities.  Thus mutations of caveolin and its 
misregulation have been closely linked to a number of disease states including heart 
disease, Alzheimer’s, and cancer (80, 81).  For example, lack of caveolin-1 leads to 
lesion formation in mouse mammary tissue that is a precursor to tumor development 
(9).  This study shows that caveolin is necessary for proper cell function and when it is 
not regulated properly it leads to disease state.  Disease states do not only occur when 
caveolin is completely silenced, another situation is where a caveolin-1 point mutation 
has occurred.  In particular, the P132L mutation is a well-known and well-studied point 
mutation in vivo.  This mutation is a naturally occurring and is found in approximately 
16% of breast cancer patients (13, 29, 31).  The P132L mutant is retained to the Golgi 
apparatus and caveolin does not reach its terminal destination in the plasma 
membrane, hence, there is a lack of caveolae.  Therefore, the expression of the P132L 
mutant results in loss of the caveolae in the plasma membrane.  Moreover, the P132L 
mutant acts in a dominant negative manner which means when both mutant and wild-
type are co-expressed, both are retained in Golgi apparatus (13).  Since it is a typical 
phenomenon that misfolded proteins are retained in Golgi it is clear that the P132L 
mutation leads to a misfolded protein, and therefore, leads to breast cancer.  Therefore, 
a definite structural change in the caveolin protein has occurred.  However, there are 
no biophysical studies that have probed the structural changes when the P132L 
mutation occurs.  For example, is it global conformational changes or local small 
changes which contribute to the non-functionality of this misfolded protein.  In this 
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study we utilized NMR spectroscopy and chemical shift indexing method to analyze 
conformational changes in the caveolin-1 transmembrane domain.  Herein, we present 
a series of experiments which will pin down the nature of the caveolin-1 P132L 
mutation.  Specifically, we will determine if the P132L mutation leads to local changes 
that will cause misfolding or global structural changes in the key transmembrane 
domain such as loss of the helix-break-helix motif.  Using NMR and CSI will be able to 
investigate this question. 
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Material/Methods 
Cloning/ Expression and Purification 
Three constructs were prepared to address questions surrounding the nature of 
the P132L mutation.  Caveolin-1(62-178), caveolin-1(96-136), and caveolin-1(122-142) 
was designed to probe P132L mutation and its effect on the global or local structural 
changes.  Both wild-type and mutants are prepared for comparison.  Preparation of 
wild-type construct of caveolin-1(96-136) and caveolin-1(122-142) is described in 
previous chapter and caveolin-1(62-178) construct was purchased from Genscript 
(Piscataway, NJ) and was prepared using the same method as caveolin-1(96-136).  All 
caveolin-1 P132L mutant constructs were prepared using the modified QuikChange 
site-directed mutagenesis method.  A primer was designed using web-based program 
primerX (Bioinformatics.org),  
5’-CATCTGGGCGGTTGTTCTGTCTATCAAATCTTGAGA-3’.   
The reaction was performed using the 9ºN ligase and pfu turbo method detailed in the 
previous chapter.  Reaction products are digested and transformed into XL-1 blue cells.  
The mutation is confirmed via DNA sequencing and is then transformed into 
BL21(DE3) cells for protein expression.  Expression was performed using the same 
method as the wild-type with Trp leader fusion protein and purification was 
accomplished using inclusion body purification method.  Detailed information 
concerning expression and purification are outlined in previous chapters.  For the 
backbone assignment of caveolin-1(96-136)P132L, uniformly 15N, 13C-labeled caveolin-
1(96-136)P132L is required.  The expression of uniformly labeled 15N and 13C caveolin-
1(96-136)P132L was prepared as described in Marley et al (58).  Moreover, to aid in 
backbone assignments specific amino acid labeling of caveolin-1(96-136)P132L was 
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employed.  Labeled amino acids were incorporated by expressing caveolin-1(96-
136)P132L according to the procedure outlined in Truhlar et al (59).  The previously 
discussed methods of purification were carried out to obtain an NMR sample (see 
chapter 1 methods section) 
Sample preparation 
For circular dichroism studies, 3 mg of protein was dissolved in 2.84 mL of TFE 
with 38.50 mg of DMPC.  This solution is injected into water and is immediately frozen 
and lyophilized to obtain a nice powder.  The powder was reconstituted with 298 µL of 
water and 12 µL of 250mM phosphate.  The sample appeared milky and vigorously 
vortexing was used to obtain homogeneity.  200 µL of 25% DHPC solution was added 
while vortexing and sample became clear.  The sample was filtered with a 0.2 µm 
regenerated cellulose spin filter to remove dust.  The concentration was adjusted using 
bicelle buffers.   
For NMR samples, 500 μL of LMPG micellar solution (100 mM LMPG, 100 mM NaCl, 
20 mM phosphate pH 7, 10% D2O) or DPC micellar solution (100 mM DPC, 100 mM 
NaCl, 20 mM phosphate pH 7, 10% D2O) was added to lyophilized caveolin constructs.  
The sample was vortexed vigorously and briefly heated in a water bath at 42 °C until 
clear.  The final protein concentration was adjusted to approximately 1 mM using a 
Biospec nano drop spectrometer operating at the 280 nm wavelength.  The clear 
solution was spin filtered through a 0.2 μm filter to remove any particulates.  The 
sample was then loaded into an NMR tube.   
CD/NMR 
Circular dichroism experiments were performed using a JASCO CD 
Spectrophotometer (Easton, MD).  The experiment was performed scanning 
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wavelength ranges of 260 to 190 nm at 25 °C.  A background spectrum was obtained 
by running a sample without protein and was subtracted.  Approximately 250 µL of 
sample was loaded into a 0.1 mm path length cuvette.  Spectra were analyzed using 
the CDSSTR algorithm in Dichroweb (45, 46, 47). 
The NMR spectra were acquired at 37 °C using a 600 MHz Bruker Advance II NMR 
spectrometer (Billerica, MA) equipped with a cryoprobe at Penn State Hershey Medical 
College (Hershey, PA).  TROSY based HSQC was performed to compare wild-type 
and P132L constructs first.  For backbone assignments of caveolin-1(96-136)P132L 
TROSY based HSQC, HNCA, and HN(CO)CA experiments were performed.  Specific 
amino acid labeling (valine, serine, leucine) was used to clarify ambiguous peaks.  The 
spectra were processed using NMRPipe and Sparky (48, 74).  Secondary structure 
information was obtained using Cα chemical shifts as described in Wishart et al (75).   
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Results and Discussion 
The naturally occurring mutant caveolin-1 P132L has been implicated in the 
pathogenesis of breast carcinomas.  To date, molecular biology experiments have 
shown that it is likely due to misfolding of the protein, however, there is no definite 
answer due to lack of structural evidence (13, 28).  Therefore, we wanted to examine 
the secondary structure of caveolin-1 P132L mutant by CD and NMR spectroscopy, 
which gives structural information.  First caveolin-1(122-142) construct was prepared in 
DPC micellar solution since DPC is a frequently used membrane mimic in the NMR 
studies and is powerful enough to dissolve caveolin-1(122-142).  The caveolin-1(122-
142) construct was chosen because the P132 residue resides at the center of the 
caveolin-1(122-142) peptide, and it is flanked by 10 residues on each side.  In addition, 
this construct will only show approximately 20 peaks in the HSQC spectrum which will 
be easy to assign the peaks.  The HSQC data of caveolin-1(122-142) shows well 
dispersed peaks in the spectra which indicate a well-structured protein.  The 
comparison of wild-type and the P132L mutant suggests there is a structural change.  
The chemical shifts of the P132L mutant are moved compared to the wild-type protein 
suggesting conformational differences but it is hard to distinguish between global or 
local conformational changes because the construct was too short (Figure 3-1).  
Therefore, we investigated a caveolin-1(62-178) construct that contains the entire 
membrane interacting portion.  First the construct was reconstituted into DPC micellar 
solution and an HSQC experiment was performed.  The number of peaks in the 
spectrum was much less than expected.  Thus detergent screening was performed to 
find a better mimic for NMR studies.  The LMPG micellar solution system was chosen 
because the spectrum was well dispersed and the number of peaks closely 
corresponds to the number of amino acids in the HSQC experiments (Figure 3-2).  
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Therefore, comparison of wild-type and the P132L mutant was performed in LMPG 
micellar solution.  The spectra of wild-type and P132L comparison show that there is 
local conformational changes not global conformational change (Figure 3-3, Figure 3-4).  
Although it is clear from these experiments that the P132L is a local structural mutation, 
peak assignments are required to indicate the nature of the structural change.  
Because of the degeneracy apparent in the spectrum, it is not easy to tackle this 
problem.  Therefore, caveolin-1(96-136) was chosen to investigate this mutation since 
caveolin-1(96-136) contains the core of caveolin-1.   
CD experiments were carried out to examine the difference between wild-type 
and P132L caveolin-1 in their global secondary structure.  Examination of these two 
spectra indicates very similar secondary structure (WT is 66% α-helicity and P132L is 
62% helicity here) (Figure 3-5).  This suggests that there is not a dramatic 
conformational change, and that the nature of the mutation results in local 
conformational changes which correspond to the results of other constructs.  To give 
additional support to the results from the CD study, NMR structural studies were 
undertaken to observe the changes that occur in the transmembrane domain of the 
wild-type versus the P132L mutant.  The NMR samples were prepared using LMPG 
detergent instead of bicelles which is used in CD studies because the concentration of 
protein in bicelles is not high enough to run NMR experiments.  First the HSQC 
spectrum of caveolin-1(96-136)P132L mutant spectrum was acquired (Figure 3-6).  
Comparison of the wild-type and mutant spectra show that mutant spectrum line widths 
are broader and the peaks are more shifted for residues adjacent to the point mutation.  
Also, several three dimensional spectra were acquired to assign the backbone as was 
done for the wild-type protein.  A specific amino acid labeling method was also 
undertaken to help backbone assignment.  Once the peaks in the spectra were 
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assigned unambiguously, we analyzed the secondary structure by using the Cα 
chemical shift index developed by Wishart et al (75).  We have confidence that this 
method is sufficient to draw conclusions as to the nature of the P132L mutant since the 
prediction of secondary structure for the wild-type protein using Cα chemical shift data 
agreed nicely with the data obtained from computer program TALOS+ which requires 
much more data input and is therefore much more restrictive (49).  As previously 
described, chemical shift indexing examines the difference between obtained Cα 
chemical shifts of the protein and compares it to random coil Cα chemical shifts to 
reveal the secondary structure of caveolin-1(96-136)P132L.  Chemical shift indexing of 
caveolin-1(96-136)P132L revealed two regions which have consecutively positive Cα 
values which indicates that the mutant chemical shift indexing was similar to the wild-
type (Figure 3-7).  Based on chemical shift indexing data, the caveolin-1(96-136)P132L 
mutant still retains the helix-break-helix motif, and therefore is similar in secondary 
structure to the wild-type protein.  Specifically, the caveolin-1(96-136)P132L mutants 
first α-helix encompassed residues 97–107 followed by a break from residues 108–110 
and then a second α-helix from residues 111–133.  After residue 133 there is an 
unstructured region from residues 134–136.  Interestingly, the secondary structure 
trend of the P132L mutant is also consistent with the horseshoe topology model of 
caveolin-1.  The break at residues 108–110 is the putative turn point that allows helix-1 
and helix-2 to be on the same side of membrane.  Therefore, CD and NMR data 
suggest that caveolin-1 P132L mutant is not changing the structure dramatically 
because the mutant contains a similar amount of α-helicity and also retained the helix-
break-helix motif which is likely to be a critical for the proper orientation of the caveolin 
protein.  We are confident that the only structural changes that have occurred are 
localized to the region of the P132L mutation as helix-1 is not affected and the break is 
still occurs at the same amino acids; Glycine, Isoleucine, and Proline.  Helix-2 started 
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at same residue at position 111 but terminated at a different residue than wild-type.  
The second helix of the wild-type protein encompasses residues 111 to 129.  This is in 
contrast with the mutant protein where the second helix was extended to residue 133.  
This means that there are four extra amino acids (1 helical turn) that are more 
structured compare to wild-type.  It is not that surprising that substituting proline to 
leucine created a more structured helix.  Proline is known to induce breaks in helical 
regions by creating kinks due to its unusual rigidity in allowed phi and psi angles.  Thus 
the mutation of the proline residue at position 132 to leucine changed the dynamic 
region to a more structured one.  Moreover, studies based on gel filtration of wild-type 
and various mutants as well as analytical ultracentrifugation show that P132L mutant 
forms a dimer whereas the wild-type behaved as monomer (28).  The extension of the 
protein by one extra helical turn is likely opening up a dimerization region around 
position 132.  In the wild-type protein the proline at position 132 is critical to cause 
helix-2 to terminate at position 129 which prevents biologically irrelevant dimerization.  
However, when proline is mutated to leucine causing the elongation of helix-2 by 4 
extra amino acids helix-2 contains an exposed dimerization region.  This could be a 
possible new mechanism based on a structural point of view to explain why this 
mutation aids in the development of breast cancer state.  As dimerization occurs, 
caveolin-1 is retained in Golgi and never reaches to the plasma membrane and leads 
to the loss of caveolae.   
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Figure 3-1.  a) 1H–15N TROSY HSQC spectrum of caveolin-1(122-142) in 100 mM
Dodecylphosphocholine micelles.  b) Overlay of TROSY-HSQC spectra of wild-type
(black) and P132L mutant (red).  
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Figure 3-2.  1H–15N TROSY-HSQC spectra of caveolin-1(62-178).  a) 100 mM 
Dodecylphosphocholine micelles. b) 100 mM lysomyristoylphosphatidylglycerol 
micelles. 
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Figure 3-3.  a) TROSY-HSQC of 15N labeled caveolin-1(62-178) (0.5 mM); 20 mM 
phosphate buffer pH 7.0, 100 mM lysomyristoylphosphatidylglycerol (LMPG), 100 mM
NaCl, 10% D2O, 37C.  b) Overlay of TROSY-HSQC of 15N labeled caveolin-1(62-
178) wild-type (black) and P132L (red). 
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Figure 3-4.  a) TROSY-HSQC spectrum of caveolin-1(62-178) with leucine residues 
15N labeled.  b) Overlay of TROSY-HSQC spectra of 15N labeled caveolin-1(62-178) 
(black), 15N labeled caveolin-1(62-178)P132L (red), and 15N leucine caveolin-1(62-
178) (green). 
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Figure 3-5.  Overlay of Circular Dichroism spectra of caveolin-1(96-136) wild-type 
(black) and P132L mutant (blue). 
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Figure 3-6.  1H–15N TROSY-HSQC spectrum of Caveolin-1(96-136)P132L. The
spectrum was acquired with 256 complex points in t1 (15N) and 2048 complex points
in t2 (1H). 
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Figure 3-7. Chemical shift analysis of caveolin-1(96–136) and caveolin-1(96–
136)P132L.  Wild-type is depicted with black bars, and the mutant is depicted with red 
bars. Caveolin-1(96–136)P132L shows an extension of helix 2 by four residues. 
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Conclusion 
Caveolin misregulation has been implicated in many different diseases 
including cancer, Alzheimer’s disease, and muscular dystrophy.  Interestingly, the 
caveolin-1 P132L mutation is found in 16% of breast cancer patients.  Many in vivo 
studies have shown that the caveolin-1 P132L mutant was retained in the Glogi but 
there is no biophysical data to clarify the mechanism.  Our over-expression system and 
reconstitution methods allow us to tackle the question of why P132L is so disruptive to 
normal caveolin-1 function.  Using NMR to solve the secondary structure, residue by 
residue information revealed conformational differences between P132L and wild-type 
proteins.  The NMR studies reveal that P132L was not changing its conformation 
globally because it still has the critical helix-break-helix motif.  Local changes are 
shown to be occurring in the caveolin-1(96-136)P132L mutant by extending the second 
transmembrane α-helical region by 4 additional amino acids at the end of helix-2 using 
chemical shift indexing NMR analysis.  This small extension might expose dimerization 
region.  Dimerization of caveolin-1 P132L mutant suggest proline has an important role 
in stopping helix-2 at position 129 but when proline is mutated to leucine it expose 
dimerization sites.  This dimerization could be a new mechanism of breast cancer.  
Dimerization sequesters caveolin-1 P132L to the Golgi and results in a loss of 
caveolae in the plasma membrane.  This finding will lead us to attain a better 
understanding of the caveolin related breast cancer pathogenesis and will ultimately 
allow therapeutic interventions to be investigated. 
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Chapter 4.  Extended Studies of Caveolin-1 Transmembrane 
Domain 
Abstract 
Caveolin-1 has a typical topology compared to most other membrane proteins.  
Both the N- and C- temini are facing towards the cytoplasm.  Based on the unique 
topology and hydrophobic characteristics of caveolin-1 a model was proposed using 
primary sequence analysis.  However, there are no detailed biophysical studies that 
support the topology model.  Therefore, various caveolin-1 constructs were prepared 
and CD and NMR spectroscopy techniques were utilized to build a topology model of 
caveolin-1.  The NMR spectrum of caveolin-1(82-136) was assigned and analyzed 
using Cα chemical shift indexing.  The data suggests that there are two α-helices of 
similar lengths in the caveolin-1(82-136); helix-1 includes residues 87-107 and helix-2 
includes residues 111-129.  In addition, caveolin-1(82-136) still contains helix-break-
helix motif like caveolin-1(96-136).  This helix-break-helix motif has similar length 
helices that may insert into lipid bilayers asymmetrically in the bilayer (confined to one 
leaflet) and curve the membrane to form caveolae.  Moreover, analysis of CD data and 
helical wheel projection show that there is an amphipathic helix at the C-terminal 
domain starting after position 143.  From this information we proposed a model of the 
caveolin-1 membrane interacting domain.  This will allow us to better understand the 
role of caveolin-1 in modulating membrane curvature.   
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Introduction 
The caveolin-1 transmembrane domain plays a critical role in various cell types 
(29, 30, 82, 83).  Although it is critical to study the transmembrane domain, the extreme 
hydrophobicity has limited progress in this area.  Until now, most of the work on 
caveolin focused on the scaffolding domain (residues 82-101) of the protein.  This 
region of the protein has been implicated as a cholesterol binding region and it is 
suspected to interact with various signaling molecules (84, 85, 86, 87, 88).  The 
scaffolding domain is a short twenty amino acid segment that immediately precedes 
the transmembrane domain.  Based on a helical wheel analysis, the scaffolding domain 
forms an amphipathic α-helical structure, which suggests that it is located at the 
surface of the plasma membrane.  Also, recent studies using synthetic peptides 
modeled after the scaffolding domain suggest that the presence of the transmembrane 
domain may be critical for the structure of the scaffolding domain.  Le Lan and 
colleagues found that the scaffolding domain was poorly structured unless five 
residues from the transmembrane domain were included in the peptide.  This data 
suggests that the conformation of the scaffolding domain may be dependent on the 
transmembrane domain, highlighting the importance of the transmembrane domain.  In 
addition, Parton and co-workers built a model of caveolin-1 based on primary 
sequence analysis.  In this model, the caveolin-1 scaffolding domain is a separate 
domain from transmembrane domain suggesting there is a break between the helix of 
the scaffolding domain and helix-1 of the transmembrane domain.  Moreover, previous 
data from caveolin-1(96-136) suggest that the first helix starts at residue Y97.  
Therefore, it is not clear that where the caveolin-1 transmembrane domain starts.  
Because the previous construct was only residues 96-136, we were not able to 
determine the starting position of the first helix.  For this reason, we designed a 
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construct encompassing residues 82 to 136 to capture the full essence of the 
scaffolding domain and the transmembrane domain which contains the critical 
horseshoe conformation of the protein.  Caveolin-1(82-136) was expressed as a Trp 
leader fusion protein to maximize the protein yield.  A methionine residue was included 
after the Trp leader sequence so that the target protein could be isolated after 
purification.  NMR spectroscopy was utilized to investigate the question of where helix-
1 of the transmembrane domain starts.  Moreover, we also designed longer constructs 
(caveolin-1(62-136) and caveolin-1(96-178)) and utilized circular dichroism 
spectroscopy in combination with CSI to elucidate other portion of caveolin-1.   
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Material and Methods 
Expression and Purification 
The genes of constructs were purchased from Genscript and inserted into pET-
24a vector containing Trp leader fusion protein as previously described.  Expression 
and purification was also performed by the same method as caveolin-1(96-136).   
For NMR studies of caveolin-1(82-136), isotopic labeling was necessary.  All 
samples were prepared as previously described except the specific amino acid labeling 
cell growth was scaled down to 500 mL and triple labeled (2H, 13C, 15N) sample was 
optimized from 13C and 15N double labeling method.  Deuterated water was used 
instead of water in M9 media and the incubation time before and after IPTG (isopropyl 
β-D-1-thiogalactopyranoside) was doubled.  Detailed methods are described in 
expression and purification chapter.   
Sample Preparation 
For NMR studies lyophilized protein was reconstituted into 500 μL of LMPG 
buffer (100 mM lyso-myristoylphosphatidylglycerol, 100 mM NaCl, 20 mM phosphate 
pH 7, and 10% D2O).  Clear solutions were obtained and subjected to 0.2 μm 
regenerated cellulose spin filter.  The final concentration was approximately 0.7 mM to 
1.0 mM.  Also circular dichorism samples were prepared in the same way as NMR 
samples using LMPG buffer without salt.  The final concentration of samples for the CD 
study was 0.2 mM.   
CD 
Circular dichroism spectra were acquired at 25°C using a JASCO circular 
dichroism spectrophotometer (Easton, MD).  A quartz cuvette with a path length of 0.1 
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mm was utilized. The spectra were obtained from 260 to 190 nm using step mode.  For 
each experiment, 8 accumulations were averaged.  A background spectrum using 
buffer was subtracted from the sample spectra.  Spectra were analyzed using the 
CDSSTR algorithm in Dichroweb (45, 46, 47).  This methodology was used for the 
following constructs, caveolin-1 (62-136), caveolin-1 (82-136), caveolin-1 (96-136), and 
caveolin-1 (96-178). 
NMR 
All NMR spectra were acquired at 37°C using a 600 MHz Bruker Avance II 
spectrometer (Billerica, MA) equipped with a cryoprobe.  For analysis and backbone 
assignments the following TROSY-HSQC-based pulse sequences were employed:  
HSQC, HNCA, HNCACB, and HN(CO)CA.  The spectra were processed using 
NMRPipe and Sparky (48, 74).  For chemical shift indexing, Cα was obtained by 
subtracting observed Cα chemical shifts from random coil chemical shifts as described 
by Wishart et al (75).  To aid backbone assignments, specific amino acid labeling was 
employed (Gly, Phe, Tyr, Leu, Ile, and Val).  All of the information was compiled and 
input into a computer program, TALOS+, to obtain dihedral angles.  This data was then 
subjected to a computer program CS-ROSETTA to obtain preliminary structure (49, 76, 
77).   
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Result and Discussion 
Caveolin-1 transmembrane domain is thought to encompass residue L102 to 
residue I134 based on primary sequence analysis.  However, previous NMR studies on 
caveolin-1(96-136) show that the transmembrane domain helix-1 encompasses 
residues Y97 to F107 and helix-2 encompasses residues L111 to A129.  It reveals that 
helix-1 is composed of 11 amino acids and helix-2 is composed of 21 amino acids.  
Moreover, the unique feature of caveolin is that N-and C- termini are facing same side.  
To build model based on this information helix-1 and helix-2 have to insert into lipid 
bilayer at different angles (Helix-1 has to insert more perpendicular to the lipid bilayer).  
But chemical shift indexing of caveolin-1(96-136) shows that helix-1 starts without an 
unstructured region unlike helix-2 which has a dynamic region at the end of helix.  
Therefore, there are two possible explanations for this result. The first possible 
explanation is caveolin-1(96-136) construct was too short to contain the full 
transmembrane domain.  So ideally helix-1 and helix-2 should be similar in length to 
insert into the lipid bilayer which the same tilt.  Second is that there is a break portion 
before helix-1 and there is another helix (scaffolding domain) to help with the 
incorporation of the caveolin transmembrane domain into bilayers.  In addition previous 
studies show that caveolin contains a scaffolding domain that occurs before the 
transmembrane domain.  However it is not clear if this domain is separate from helix-1 
or is a continuation of helix-1.  Therefore we extended the transmembrane domain 
construct to investigate structural aspects of the enlongated construct, caveolin-1(82-
136).  The expression and purification methods were performed using a similar method 
to caveolin-1(96-136).  Also pure caveolin-1(82-136) was reconstituted into LMPG 
micellar buffer and subjected series of NMR experiments.   
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Figure 4-1.  Assigned 1H-15N TROSY-HSQC spectrum of caveolin-1(82-136) in 100
mM 1-myristoyl-2-hydroxy-sn-glycero-3-phospho-(1'-rac-glycerol) micelles; 100 mM
NaCl; 20 mM phosphate pH 7.0.  The spectrum was acquired with 256 complex
points in the t1 dimension (15N) and 2048 complex points in the t2 dimension (1H). 
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Figure 4-2.  Chemical shift index plot of caveolin-1(82-136).  Helix1 spans residues 
87-107 and helix2 spans residues 111-129.  The break between helix1 and helix2 
spans residues 108-110. 
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To assign the backbone resonances employing NMR experiments, uniformly labeled 
caveolin-1(82-136) (2H,13C, 15N ) in LMPG micelles was performed using the following 
two and three dimensional TROSY-HSQC-based experiments: HSQC, HNCA, 
HNCACB and HN(CO)CA (Figure 4-1).  Because of degeneracy, specific amino acid 
labeling was employed to aid in backbone assignments (Gly, Phe, Tyr, Leu, Ile, and 
Val).  Based on Cα chemical shift indexing, residues 87-107 and residues 111-129 
have consistently positive ∆Cα’s which is indicative of  an α-helical structure and 
residues 108-110 which are in between do not have positive ∆Cα’s (Figure 4-2).  Thus 
caveolin-1(82-136) still has helix-break-helix motif and helix-1 starts at position A87 
instead of Y97.  The transmembrane domain is comprised of two α -helices of near 
equal length.  Helix 1, residues 87-107, is composed of 21 amino acids (a length of 
31.5 Å), helix-2, residue 111-129, is composed of 19 amino acids (a length of 28.5 Å). 
No break was observed before residue Y97 which suggests that the scaffolding domain 
is a part of helix-1.  Moreover, these similar lengths of two helices will insert caveolin 
into bilayer in similar angles.  The preliminary model was created inputting compiled 
information into CS-ROSETTA computer program (Figure 4-3). 
Next, we investigated two extended caveolin-1 transmembrane domain 
(residues 62-81 and residues 137-178).  Previous studies show that caveolin-1 N-
terminal domain is unstructured dynamic portion of the protein (17).  To investigate this 
we extended construct from residue 62 to 136.  Comparison of caveolin-1(62-136) and 
caveolin-1(82-136) could obtain information about residues 62-81.  To obtain 
information of C-terminal domain we designed construct from reside 96 to 178.  
Comparison of caveolin-1(96-136) and caveolin-1(96-178) could obtain information 
about residues 137-178.  The construct was prepared using the same methodology as 
previous described.  The key difference of this study from other studies is that we 
 130 
contain core of the caveolin protein (helix-break-helix motif).  However, it is not feasible 
to examine the entire construct using NMR to obtain Cα information that can be used to 
analyze the secondary structure residue by residue using chemical shift indexing 
because of the degeneracy of the spectra.  Therefore, we used circular dichroism 
spectroscopy to obtain global secondary structure information.  Helical wheel analysis 
was also performed to investigate the C-terminal domain.  Samples were prepared in a 
LMPG buffer similar to that used for analyzing the NMR samples but without salt in 
order to prevent light scattering.  The previous chapter analyzing caveolin-1(96-136) 
show that 30 residues are α-helical (11 residues in helix-1 and 19 residues in helix-2) 
which is 73% α-helicity based on CSI.  The circular dichorism data of caveolin-1(96-
136) analyzed by CDSSTR method in Dichoweb show that 79% is α-helical which 
corresponds to 32 amino acid residues.  In addition, caveolin-1(82-136) chemical shift 
indexing show that 40 residues are α-helical (helix-1 contains 21 residues and helix-2 
contains 19 residues) which is 73% α-helicity.  CD data analysis of caveolin-1(82-136) 
shows that 74% is α-helical which corresponds to 41 residues.  From this comparison, 
the CD percentage values of α-helicity converted to the number of amino acids are well 
in the agreement with the number of amino acids analyzed by the chemical shift 
indexing method (approximately 1-2 amino acid error range).  This indicates that CD 
analysis is accurate enough to obtain the number of amino acids that correspond to the 
α-helix.  A series of the spectra obtained from different truncated constructs were 
analyzed using the CDSSTR algorithms (Dichroweb). The analyses indicate that 
approximately 79%of caveolin-1(96-136) is α-helical, caveolin-1(96-178) is 78% α-
helical, caveolin-1(82-136) is 74% α-helical, and caveolin-1(62-136) is 72% α-helical 
(Figure 4-4).  Therefore, caveolin-1 is mainly composed of α-helical secondary 
structure.  To investigate 62 to 81 regions, CD data of caveolin-1(62-136) and CSI data 
of caveolin-1(82-136) were taken for comparison.  From CSI analysis caveolin-1(82-
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136) contains 40 amino acids that are α-helical.  From CD data analysis caveolin-(62-
136) has 72% α-helical which corresponds to 52 amino acids.  The combination of 
these two results show that residues 62-81 contain 12 amino acids that have α-helical 
properties and 7 amino acids that have unstructured character.  To figure out where 
this helix is, we made an assumption that proline at position 75 induces a break in the 
helix like the other prolines in the transmembrane domain.  Therefore, a 12 amino acid 
long α-helix has to be before or after proline at position 75.  But to place 12 amino 
acids α-helix after proline at 75 is not likely to occur.  Because if the helix starts right 
after proline at position 75 the 12 amino acid long helix will end at residue 87.  This 
means the caveolin-1 transmembrane domain helix-1 extend to residue 76 since 
transmembrane domain of helix-1 the starts at residue 87.  Based on CSI, residues 82-
86 are unstructured which suggests the 12 amino acid long helix cannot be after 
proline 75.  Therefore, a 12 amino acid long helix will be before proline 75 which will 
create a helix starting at residue 62 or 63.  Another possibility is a kinked helix (helix-
break-helix motif) is present around proline at position 75 if the assumption is incorrect.  
However, because of limitations of CD spectroscopy it is difficult to address this 
question.   
To investigate the C-terminal domain of this protein, caveolin-1(96-136) and 
caveolin-1(96-178) data were compared.  The CSI analysis of caveolin-1(96-136) 
shows that 30 amino acids are α-helical.  The CD data analysis of caveolin-1(96-178) 
shows that 78% are α-helical which mean 65 amino acids have α-helix properties.  
From this information we can conclude that approximately 35 amino acids are α-helical 
in the C-terminal domain of the protein (residue 137-178) and 5 amino acids are 
unstructured.   
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To pin point where this helix starts, analysis of primary sequence was 
performed using helical wheel analysis (Figure 4-5).  Based on in vivo studies, there 
are three cysteine sites that are responsible for palmitoylation in the C-terminal domain 
at position 133, 143, and 156.  To avoid the penalty of placing a palmitoyl group into 
the cytoplasm the three cysteine sites have to face membrane.  However, the cysteine 
at position 143 is opposite to other cysteine sites that are not facing the membrane if 
the helix starts at residue 133 based on helical wheel analysis.  Therefore, the helix 
has to start after residue 143 for all three cysteine sites because facing pamiltoylated 
cysteine sites towards hydrophilic environment is not energetically favorable.  
Moreover, caveolin-1(96-136) CSI shows that residues 130 to 136 are dynamic.  
Residues up to 143 must be unstructured to keep residue 143 facing membrane and 
this result is consistent with CD data, agreeing with number of helical residues.  From 
this analysis, 7 amino acids are unstructured (5 unstructured amino acids ± 2 amino 
acids).  Adding 7 amino acids after 136 will make unstructured region up to position 
143.  Therefore, C-terminal amphipathic helix will start after cysteine 143 and will go to 
the end of sequence.  Using the combination of all this data, we can propose a model 
that contains the complete membrane interacting domain of caveolin-1 based on 
experimental data (Figure 4-6).   
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Figure 4-3.  Circular dichroism spectra of various caveolin constructs in 100 mM
LMPG; 20 mM phosphate pH 7.0.  a) Caveolin-1(82-136) (solid line) and caveolin-
1(62-136) (dashed line).  b) Caveolin-1(96-136) (solid line) and caveolin-1(96-178) 
(dashed line). 
 134 
 
I144
S145
R146
V147
Y148
S149
I150
Y151
V152
H153
T154
V155
C156
D157
P158
L159
F160
E161
A162
V163
G164
K165
I166
F167
S168
N169
V170
R171
I172
N173
L174
Q175
K176
Polar Non-Polar
Figure 4-4.  Helical wheel projection of caveolin-1(144-178).  Charged residues are 
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Figure 4-5.  Preliminary model of caveolin-1(82-136) based on CS-ROSETTA. 
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Figure 4-6.  Topology model of caveolin-1 in a DMPC bilayer. 
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Conclusion 
Approximately 50% of caveolin-1 is interacting or associated with the 
membrane.  It is critical to elucidate the structure of the caveolin-1 membrane 
interacting domain.  The structural analysis of the entire caveolin-1 membrane 
interacting domain is essential to understand role of caveolin-1.  In this study we used 
CD and NMR spectroscopy to investigate the membrane interacting domain of 
caveolin-1.  CSI indexing compiled from NMR data shows that the caveolin-1 
transmembrane domain has a helix-break-helix motif and the first helix encompass 
residues 87-107 and the second helix encompass residues 111-129.  Moreover, other 
putative membrane interacting helices are observed using the combination of CD and 
CSI.  From this information we could propose a model based on experimental results.  
The transmembrane domain inserts into the lipid bilayer symmetrically and there is a 
long amphipathic helix in the c-terminal domain starting after residue 143.  This is the 
first model caveolin-1 based on experiments and this model will provide better insights 
into the role of caveolin-1.   
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Chapter 5. Bicelles and Application 
Abstract 
Membrane mimics are critical to study membrane proteins in vitro.  Until now, 
micelles and vesicles are the two most utilized systems to study membrane proteins.  
For solution NMR structural studies, micelles are the most common mimic to gather 
structural information since vesicles are huge and do not tumble fast enough.  Although 
the micelle system is excellent to apply to solution NMR studies for membrane proteins, 
the drawback is that micelles do not have a planar bilayer region and the high 
curvature of micelle can create structural artifacts.  Therefore, better systems are 
required to obtain more accurate structural information.  The bicelles are discodial lipid 
aggregates composed of long and short chain lipids.  The long chain lipid of bicelles 
creates planar bilayer and short chain lipids encapsulate the rim.  The different ratio of 
long and short chain lipids (q) enables the use of bicelles to both solid and solution 
state NMR studies.  Incorporation of various caveolin-1 constructs (especially 96-136) 
is performed to find out the best way to reconstitute membrane protein into bicelles 
such as preforming bicelles, modified ethanol injection, and PFOA vesicle methods to 
apply to solution NMR studies.  In addition, other applications of bicelles are studied 
instead of their use as a membrane mimic for solution NMR studies.  Periodic meso-
porous material was developed using bicelles and micelles.  Since bicelles have 
unique properties that micelles do not have like size tuning and magnetic field 
alignment they may be desirable in the generation of novel porous materials.  The 
different lipid concentration bicelles are tested with q=0.5 value.  Moreover, bicelle and 
tetramethoxysilane (TMOS) concentration was varied to obtain porous materials.  The 
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material obtained using bicelles had novel pillared lamellar structure with high surface 
areas. 
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Introduction 
A major hindrance of studying membrane proteins in vitro has been a lack of 
“native-like” medium which can support structure, function, and activity.  Most often and 
most widely, detergents are used to solubilize membrane proteins.  However, 
detergents are not the best mimic of the membrane for biophysical studies for several 
reasons.  First, detergents usually lack the characteristics of natural phospholipids 
which can bias structural determination.  Second, the high curvature of micelles could 
create artifact in the structures.  Lastly, micelles do not have true bilayer to support 
membrane proteins.  Another heavily used membrane mimic is vesicles.  Vesicles are 
used instead of micelles for membrane protein studies since they have a true bilayer 
and are therefore most similar to the cell membrane system.  It is a good mimic to 
study functions but for structural studies such as NMR it is not adoptable because of 
the large size and lack of dynamic properties of vesicles.  Therefore, a better mimic of 
the membrane is desirable to obtain more accurate structural information of membrane 
proteins.  In particular, a bilayer with phospholipids would serve as a better 
environment for membrane proteins such as vesicles and sufficient fast reorientation 
rates like micelles to able to obtain high resolution solution NMR spectra for structural 
determination. 
The bicelles have become promising model for structural studies using NMR 
and other functional studies.  A bicelle is a discoidal lipid aggregate composed of long 
chain phospholipids and detergent or short chain phospholipids (Figure 5-1).  The 
features of bicelles have a combination of advantages from both vesicles and micelle 
system.  Bicelles have a true bilayer like vesicles and dynamic properties like micelles.  
The structure of bicelles have a central bilayer formed by the long-chain phospholipid 
and are encapsulated by a ring of detergent or short chain lipids that shields the long-
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chain lipid tails from water.  The central bilayer region is most commonly composed of 
DMPC and the rim region is composed of either a bile-salt derivative such as CHAPSO 
or a short-chain phospholipid such as DHPC (33, 34, 35, 36, 37, 38, 39).  There are 
several advantages in bicelles.  First, the thickness can be changed by using other 
chain length phospholipids instead of DMPC.  Second, the surface charge can be 
changed.  The bilayer region can be doped with phospholipids that have identical chain 
lengths but different head groups in order to alter the charge characteristics of the 
membrane.  Lastly, important advantage of bicelles is that their size and properties can 
be varied by altering both the total lipid concentration and the molar ration (q) of DMPC 
to that of DHPC.  For most solution phase NMR experiments, bicelles with a q value of 
0.5 are utilized.  At this q the bicelles still have an appreciable bilayer region (82 A 
diameters) to accommodate full-length proteins and they tumble fast to have sufficient 
reorientation times. 
The attention to periodic meso-porous materials is growing fast because of 
variety applications such as catalysis, separation, chemical storage, and delivery (89, 
90).  The most widely employed method is templation of micelles especially using 
cationic or non-ionic detergents (91).  The new micelle system was a driving force of 
the fast growth of this area in material science because different micelle systems 
produce different meso-porous materials.  However, there is a limitation using micelle 
systems like similar pore size because pore size is dependent on the size of micelles.  
To circumvent this problem bicelles systems are applied to obtain new periodic meso-
porous materials.  The ability of tuning size of bicelles and the altering charges of head 
group will open up new perspective for templating. 
In this chapter, various method of incorporation of membrane protein especially 
caveolin-1(96-136) was performed to find out best way to incorporate membrane 
 142 
proteins into bicelles.  Moreover, investigation of application of bicelles for templation of 
periodic meso-porous materials will be introduced. 
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Figure 5-1.  Schemetic representation of DMPC bicelles with DHPC rim. 
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Material/ Methods. 
Preparation and incorporation of membrane protein into bicelles 
Modified Ethanol injection method. 
38.5 mg of DMPC and 3mg of Caveolin-1(96-136) were dissolved into 2.84 mL 
TFE.  Inject into 50 mL of water quickly and freeze immediately.  The sample was 
lyophilized to achieve a nice fluffy powder.  The sample was then vortexed vigorously 
to obtain milky homogeneous solution in 310 µL of 20 mM phosphate buffer.  200 µL of 
25% (w/w) DHPC was added while mixing to form clear bicelles solution. 
Co-lyophilization method 
38.5mg of DMPC and 3mg of Caveolin-1(96-136) were dissolved in 5mL of 
50% HFIP and lyophilized immediately.  The sample was vortexed until milk-like 
suspension is obtained in 310 µL of 20 mM phosphate buffer.  200 µL of 25% (w/w) 
DHPC was slowly added into resuspended DMPC while mixing.  After an extra one 
minute of voltexing, clear bicelle solution is obtained. 
Preforming bicelle method 
38.5 mg of DMPC was resuspended with 310 µL of 20 mM phosphate buffer 
water and voltexed until homogeneous milk-like suspension is obtained.  200 µL of 
25% (w/w) DHPC was slowly added into resuspended DMPC while mixing.  After an 
extra one minute of voltexing, clear bicelle solution is obtained. The solution was spun 
for one hour at 20,000xg to remove bubbles from the solution.  3 mg of lyophilized 
caveolin-1(96-136) was added to preformed bicelles. 
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PFOA dialysis method 
38.5 mg of DMPC and 3 mg of caveolin-1(96-136) were dissolved in 2.84 mL of 
PFOA buffer (300 mM PFOA and 10 mM Tris, pH 8).  Place dissolved sample in hot 
water until solution turns clear.  Load into 10,000 molecular weight cut off dialysis 
cassette and dialyze against 2-liter of 10 mM ammonium sulfate, pH 8.  Dialysis was 
performed for 3 days with every 12 hour buffer exchange and final exchange was 
performed with NMR buffer condition (100 mM NaCl and 20 mM phosphate, pH 7).  
200 µL of 25% DHPC was added and concentrated to obtain proper volume. 
Templating for meso-porous materials 
1 mg of ammonium fluoride was dissolved in bicelle solution and added 218 mg 
of the tetramethoxysilane (TMOS). During the addition of the tetramethoxysilane, the 
bicelle solution was continuously sonicated at room temperature. After the addition of 
the TMOS a white precipitate formed immediately. The mixture was sonicated for 
another 2 min and the precipitate was filtered off, washed with acetone, and vacuum-
dried at room temperature (92). 
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Result and Discussion 
Bicelles are a mimic of the membrane that has both advantages of micelles and 
vesicles.  It has the dynamic properties of micelles and a planar bilayer region like 
vesicles.  Bicelles are a great medium to study protein lipid interactions in the solution 
NMR state.  In addition, bicelles can adopt cholesterol up to 20% which will be useful to 
study membrane proteins that have interactions with cholesterol.  However, it is not as 
commonly used to perform membrane protein structural studies compared to micelles 
because it is not easy to incorporated membrane proteins into bicelles especially at the 
concentration for NMR experiments.  In addition most research has found that there is 
little difference in secondary structure of protein when it is observed in micelles and 
bicelles.  However, there is no doubt that bicelles are a better mimic of the membrane 
and further studies can be only achieved using bicelles such as protein-lipid NOEs.  
Therefore, incorporation of caveolin-1(96-136) constructs was performed to optimize 
incorporation methods.  First, a preforming bicelle method was performed.  Bicelles are 
prepared by mixing DMPC and DHPC with buffer and loaded into micro centrifuge 
tubes that contained lyophilized caveolin-1(96-136).  As caveolin-1(96-136) was 
incorporated high concentration to achieve NMR concentration precipitation usually 
occurred.  This may result of caveolin-1(96-136)’s extremely hydrophobic nature.  It is 
possible that some of caveolin-1(96-136) interacts with each other before protein have 
chance to interact with lipids.  Thus other methods are employed to address this 
problem.  The modified ethanol injection method was performed using TFE instead of 
ethanol which is a well-established method to obtain unilamellar vesicles.  To make 
sure caveolin-1(96-136) was well mixed with lipid to ensure chances of interacting with 
lipids are higher than aggregation process.  A homogeneous milky suspension was 
obtained after resuspension with phosphate buffer but still some precipitated out when 
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DHPC was added.  This may be because TFE is not strong enough to break down 
aggregation in the first place.  Therefore, co-lyophilizing caveolin-1(96-136) with DMPC 
lipid using the HFIP method was utilized.  However, precipitation was still observed as 
increment of concentration.  This result lead us to believe it may be that lyophilization 
was too harsh for the vesicle system with caveolin-1(96-136).  Vesicles can burst when 
lyophilization is taking a place to remove water inside and the protein is not situated 
properly in the vesicles and when hydrated with buffer and some protein which is not in 
the right conformation will precipitate out.  Therefore, we adapted the method forming 
vesicles with PFOA.  PFOA is perfluorinated detergent which is powerful enough to 
solubilize inclusion bodies.  The caveolin-1(96-136) and DMPC was dissolved in PFOA 
buffer and dialyzed a couple of days with extensive buffer exchanges to form vesicles 
in the most gentle way.  Most of the PFOA was removed in the first 12 hours and 
vesicles were formed within 3 days.  After obtaining vesicles DHPC was added to form 
bicelles and the precipitation was not observed immediately.  But the problem was the 
volume of sample was higher than we needed.  Therefore, a method to keep volume 
suitable for NMR experiments was required.  A concentration method was performed to 
obtain required volume size but tremendous protein loss was observed after 
concentration.  Therefore, the drying down method was performed but the protein 
started precipitating out as soon as the required volume is reached.  From these 
experiments, the incorporation of caveolin-1(96-136) construct into bicelles for CD 
studies was achieved but not for NMR studies.  As caveolin-1(96-136) was titrated into 
bicelles system using various methods it was clear that bicelles can handle up to a 
certain concentration but it is not high enough for NMR experiments.  Tuning the bicelle 
size was also performed to check preference of size of bicelles for caveolin-1(96-136).  
The sizes were q=0.2 to 1.0 with 15% lipid concentration.  Also the concentrations of 
bicelles are brought up to 20% to check concentration of lipid will help incorporation.  
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However, the incorporation of caveolin-1(96-136) in bicelles suitable for NMR studies 
was not achieved.  More optimization is required to obtain high concentration of 
membrane protein into bicelles such as changing the length of long chain lipids or 
charge of lipid head group. 
Instead of using bicelles as mimic of membrane, bicelles were adopted for the 
use as a template of periodic mesoporous materials.  Until now, micelle systems were 
the most commonly used template for periodic mesoporous materials.  However, using 
bicelles as template has several advantages because bicelles can tune the size of 
pores.  For these studies, different concentrations of bicelles are utilized, 5%, 12%, and 
20%.  Also the ratio of TMOS and bicelles was varied to investigate effect of formation 
of meso-porous materials.  From data the ratio between TMOS and bicelles is critical to 
form novel hexagonal pillared lamellar structure or non-pillared lamellar structure (92).  
Higher concentration of TMOS lead to novel hexagonal pillared lamellar structure 
(Figure 5-2).  The meso-porous material that is created by using 5% bicelles 
concentration with higher concentration of TMOS for approximately 2 minutes of 
reaction time showed that the material has a very high surface area.  These data 
suggest that bicelles can be adapted to other applications and not only to membrane 
protein research. 
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Figure 5-2.  Schemetic representation of bicelle templated silica structure.  
Grey: bicelles, Orange: silica layers, Green and blue: silica pillars. 
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Conclusion 
Bicelles have been characterized and applied as a membrane mimic for 
membrane protein studies.  In particular, the advantages of bicelles are desirable for 
membrane protein NMR.  The magnetic alignment property of high q bicelles facilitates 
the application of bicelles to solid state NMR structural determination.  The fast 
tumbling property of low q bicelles enables bicelles to be adapted in solution state 
NMR structural determinations.  Therefore, various methods of reconstituting caveolin-
1 constructs into bicelles were performed but none of the methods are able to reach 
solution NMR concentration (approximately 0.5-1.0 mM concentration).  Because the 
function of caveolin-1 is proposed to curve cell membrane, it may destabilize bicelles at 
high concentration.  More optimization is needed to incorporate caveolin-1 constructs 
into bicelles such as changing the head group of lipids to change surface charges or 
change the lipid tail length to find the optimum length for proteins.  Although 
incorporation of caveolin-1 constructs into bicelles is not easy they still have the 
potential to be used in place of micelle systems for solution NMR studies.  Bicelles can 
also be applied to other studies that use micelle systems as a membrane mimic.  The 
formation of periodic meso-porous materal was performed and displayed novel 
hexagonal pillared lamellar structure.  The advantage of tuning the size of the bicelles 
could open more possibilities of different size porous materials.  Moreover, the 
magnetic alignment property of bicelles is alluring to add new perspective to templating 
such as magnetic field directed templating.  Perspective porous material applying 
bicelles for templating can be applied in the biophysical studies, and may serve as new 
medium for membrane protein alignment for solution NMR studies to obtain long range 
restraints. 
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A study of the gold(I)-catalyzed intramolecular hydroamination of trichloroacetimidates 
derived from propargyl and homopropargyl alcohols. 
 
TEACHING EXPERIENCE 
Teaching Assistant, 2006 – 2011 
Lehigh University, Bethlehem, Pennsylvania 
Courses: General Chemistry Lab (Chem 30)  
Fall 2006, Spring 2007, Fall 2007, Spring 2008, Summer 2008, Fall2008, 
Spring 2009, Fall 2009, Spring 2010, Fall 2010 
Organic Chemistry Lab (Chem 51) 
Summer 2007, Summer 2010 
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Topological Model.” Manuscript in preparation. 
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Lee, J.; Glover, K.J., “The transmembrane domain of caveolin-1 exhibits a helix-break-
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Mohanty, P.; Lee, J.; Glover, K.J.; Landskron, K., “Discoid bicelles as efficient 
templates for pillared lamellar periodic mesoporous silicas at pH 7 and ultrafast 
reaction times.” Nanoscale Res. Lett. 2011, 6, 61-65.  
Diefenderfer, C.; Lee, J.; Mlyanarski, S.; Guo, Y.; Glover, K.J., “Expression and 
Purification of Transmembrane Domains for Biophysical Studies.” Analytical 
Biochemistry 2009, 384, 274-278. 
Kang J.E.; Kim H.B.; Lee J.W.; Shin S., "Gold(I)-Catalyzed Intramolecular 
Hydroamination of Alkyne with Trichloroacetimidates" Org. Lett. 2006, 8, 3537–3540. 
* denotes co-first authors. 
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PRESENTATIONS 
Biophysical Society Pennsylvania Network Meeting, September 2012 
-Poster presentation: Revealing the structure of the transmembrane domain of 
caveolin-1. 
FASEB conference (Molecular Biophysics of Membrane), June 2012 
-Talk and Poster: Revealing the structure of the transmembrane domain of caveolin-1 
Delaware Membrane Protein Symposium, May 2012 
-Poster presentation: Revealing the structure of the transmembrane domain of 
caveolin-1. 
Biophysical Society, March 2011 
-Poster presentation: Investigation of the three-dimensional structure of the caveolin-1 
membrane interacting domain.   
Delaware Membrane Protein Symposium, May 2011 
-Poster presentation: Investigation of the three-dimensional structure of the caveolin-1 
membrane interacting domain. 
Delaware Membrane Protein Symposium, November 2009 
-Poster presentation: Insights into the Secondary Structure of Caveolin.  
 
AFFILIATIONS 
Sigma Xi, 2010 – present 
American Chemical Society, 2010 – present 
Biophysical Society, 2011 – present 
 
AWARDS 
Student Chemistry Foundation Fellowship, 2011-2012  
 
